Idan kun ji likitan likitan ku, likitan ku, ko shugaban jami'a na ilimi da mummunan yanayin da aka lalata na "Ivermectin baya aiki don Covid"ko kuma akwai"babu shaida"Ko "babu data" don tallafawa amfani da ivermectin a cikin Covid-19, aika musu wannan taƙaitaccen nazari na meta da taƙaitaccen tarihin binciken sama da 100.
Ban taba lallaba da ra'ayin social media ba, shi ya sa ban taba yin rajista ba. Ban da pathological zamantakewa dalilai, Ina tsammanin wani tsari ne na rashin hankali na musamman ga masana kimiyya masu tsanani don fara muhawara game da rikice-rikice da rikice-rikice na binciken likita, ilimin likitanci, ko kula da haƙuri.
Ba ni da asusun Twitter/X amma kwanan nan na ƙirƙira ɗaya bayan abokan aikina sun tuntube ni suna faɗakar da ni ga rubuce-rubuce daga Dr. Peter Hotez sukar kwanan nan na shaida gaban Majalisar Zabi Karamin Kwamitin kan Cutar Coronavirus wanda Dr. Brad Wenstrup (R-OH) ya gudanar. Dr. Hotez a likitan yara da magungunan wurare masu zafi Dean Baylor a Houston, Texas. Kimanin makonni shida bayan haka, Dr. Hotez ya amsa shaidata akan Twitter/X:
Na yi ƙoƙari na karyata maganar Dr. Hotez ta hanyar kafa asusun Twitter/X kawai don gano cewa ba zan iya ba! Ban san cewa hanya daya tilo na yin tsokaci kan shafin Dr. Hotez na jama'a na Twitter/X shine ya kasance ya ba shi izinin yin haka!! Kuma a nan na yi tunanin ra'ayin Twitter shine don inganta maganganu; ba takura shi ba.
Ra'ayoyin waje BABU MARABA: Hoton hoto daga asusun Dr. Hotez na Twitter/X lokacin da na yi ƙoƙarin mayar da martani ga wulaƙanta shaidar da na yi na majalisa.
Tabbas ya bayyana cewa ra'ayoyin kimiyya masu sabani ne ba maraba a shafin Dr. Hotez na Twitter/X.
Dokta Hotez ya soki shaidata ba gayyata don tattaunawa game da cancanta ko gazawar maganin ivermectin; “harbi-harbi ne na alama” yana bayyana cewa shaidar da na rantse na Majalisa ita ce:
- "lalata bayanan kimiya mai haɗari, mai tsabta da sauƙi” da wancan
- "Ivermectin ba ya yin komai don taimaka wa mutanen da ke da Covid"Kuma
- "Ivermectin baya aiki ga Covid"
Na biyu (a cikin jerin gajerun gajerun dozin dozin, tweets na gaba na Dr. Hotez) ya kasance filin wasa don littafinsa.
Dakta Hotez sai “ya ɗaukaka” kuma ya sake buga rubutu daga ɗaya daga cikin zaɓaɓɓun mabiyansa wanda ya bayyana a matsayin mai gudanarwa na Twitter na wani nau'i. Wannan mutumin da murna ya furta cewa shaidara ta kasance "al'umma-lura" tare da cewa "Yawancin ingantaccen binciken kimiyya sun nuna cewa ivermectin shine gaba daya mara tasiri"(ƙara da ƙarawa) da"inganta Ivermectin don raunin alurar riga kafi yana sanya rayuka cikin haɗari.” Maganar ƙarshe ita ce sleight na hannu, kamar yadda ban taɓa yin ra'ayi game da amfani da ivermectin don "raunin alurar riga kafi” a kowane lokaci a lokacin shaidata ko a cikin wani rubutu na da ya gabata.
Rubutun jama'a na Twitter an yi niyya ne don ba da mahallin ga abubuwan da ke da bayanan da za a iya muhawara, tare da wannan, wanda ke nufin "ƙara" shaidara, mai ɗauke da hanyoyin sadarwa guda bakwai (7). Biyu daga cikin hanyoyin haɗin sun kasance kwafi, suna nufin ainihin bayanai iri ɗaya (lambobi 1 da 3 da lambobi 2 da 7). Sun yi nuni da binciken JAMA ko NEJM wanda su kuma masana ilimi suka yi suka da cewa suna da gazawar kimiyya da na asibiti sosai. Kodayake bayanin kula ya kuma bayyana cewa "haɓaka ivermectin don 'rauni na rigakafi' yana jefa rayuka cikin haɗari," babu ɗayan waɗannan hanyoyin da aka ƙaddara cewa amfani da ivermectin yana haifar da "haɗari." Lokacin da aka tsara shi daidai, ivermectin ba wai kawai an ƙaddara ya zama lafiya ba, amma tarihi ya tabbatar da kansa "mamaki lafiya. "
Hanya na biyu zuwa na ƙarshe na “bayanin kula na al’umma” shine a mahada mara aiki zuwa gidan yanar gizon FDA. Bai yi aiki ba saboda FDA ta amince ta share shi sama da wata ɗaya a baya a matsayin wani ɓangare na sasantawa na doka don rashin dacewa da amfani da ivermectin. Shin ma'aikatan Twitter/X "bayanin kula da al'umma" ba su damu ba don danna hanyoyin haɗin don tabbatar da cewa sun yi aiki kafin a ba da izinin buga su azaman nassoshi? Daga ƙarshe, wasu mutane sun lura da gazawar "bayanin kula da jama'a" kuma saboda an cire shi da sauri duk da cewa "Ya ambaci tushe masu inganci. "
Hoton ainihin “bayanin kula na al’umma” tare da ƙarin kibiyoyi masu nuna takamaiman wurare ana nuna su a ƙasa:
Tabbas ni kaina ko wani mutum ba zai iya cin karo da wadancan ikirari ba saboda dukkanmu Dr. Hotez ya hana mu yin rubutu. Ya bayyana cewa zai gwammace ya yi wata magana da ba ta dace ba, sannan ya cusa yatsunsa a cikin kunnuwansa bayan ya gama fadin abin da zai yi, ya guje wa duk wata tattaunawa da za ta iya yi, yayin da fastocinsa na “amincewa” suka yi ta tururuwa don kada kuri’a a kansa – amma duk da cewa akwai yuwuwar fuskantar takaddama. ba za a iya buga.
Ba tare da izini daga waje ba, wannan yana nufin Dr. Hotez ya "lashe" muhawarar?
Sai ya zama abin da na yi a Twitter ya ɓace kuma ya ɓata lokaci. Asusu na Twitter/X yana yanzu tarihin. Duk da yake yana aiki mai girma ga ɗimbin al'amura daban-daban, a bayyane yake wuri ne marar hankali ga mutum mai tsanani ya yi ƙoƙari ya tattauna ko muhawara game da rikitattun kimiyyar likitanci ko kula da haƙuri. A wannan lokacin, ba ni da niyyar komawa.
Yin watsi da Binciken Bayanai a Tarihi: Copernicus da Galileo
Ijma'i yana da mahimmanci ga wasu, amma abin takaici, ba shi da alaƙa da kimiyya. Kimiyya ba ta damu da ijma'i ba. A haƙiƙa, da yawa daga cikin manyan ci gaban kimiyya sun samo asali ne na tambayar ƙaƙƙarfan yarjejeniya. Ƙirƙirar yarjejeniya don sabon batu, mai rikitarwa na iya zama musamman hatsari. Lokacin da mutane suka yarda sun kasance suna tallafawa juna, amma akwai haɗari cewa sun manta cewa suna sake tabbatar da wani kuskuren kuskure ko rashin daidaituwa saboda yanke shawara nasu yana da ban sha'awa da / ko yana faruwa a cikin sarari.
Kusan keɓancewar ba da izinin amsawa mai ma'ana ga kansa, Dokta Hotez ya kasa yin la'akari da cewa an noma shi ta hanyar wucin gadi tare da ainihin rashin yarda mai ma'ana da aka yarda ya faru. Bugu da ƙari, kasancewa mai adawa da 'yancin faɗar albarkacin baki, babban misali ne ga masanin kimiyya ya kafa, musamman ga wani a matsayin farfesa mai ilmantar da masana kimiyya na gaba. Mafi kyawun masana kimiyya su ne waɗanda suke shirye su saurari ra'ayoyin wasu masu hankali kuma suyi la'akari da hujjojinsu.
Tarihi ya nuna mana cewa yin watsi da hujjojin kimiyya da kawar da rashin amincewa ba su da kyau ga ci gaban fasaha; wani abu da farfesa wanda kuma ya yiwa kansa lakabi da "jarumin kimiyya" a kan kansa homepage tabbas ya kamata ya riga ya sani.
Misalin littafi na "anti-kimiyya" shine lokacin da Copernicus da Galileo suka yi ƙoƙari su ciyar da ra'ayoyin cewa duniya tana jujjuya rana (saɓanin labarin geocentric na duniya kasancewar tsakiyar sararin samaniya, wanda duk abubuwan sararin samaniya suke juyawa). An yi banza da Copernicus da Galileo kuma an hana rubuce-rubucensu. Su biyun wani kwamitin takwarorinsu ne ya yi shari’a, aka same su da laifi, aka cire su daga mumbarin fafutuka, aka kama su, aka daure su. Daga ƙarshe an ƙyale Galileo ya rayu cikin sauran shekarunsa, an yi masa hijira a ƙarƙashin “kame gida” a gona. Amma duk da haka, aƙalla an baiwa Copernicus da Galileo damar yin jayayya da gabatar da shaidarsu… ba kamar yadda Dr. Hotez ya toshe shafin Twitter ba.
Magani ba kasafai ba ne "Baƙar fata ko fari"
Duk da ci gaban shekaru da yawa, kimiyyar asibiti ba safai ba ce baƙar fata ko fari. Da wuya a sami sanarwar "faufau"Ko"kome ba"Ko"gaba daya."Har yanzu, Dr. Hotez akai-akai yana yin polarizing, binary black-ko-fari, dama-ko-kuskure ikirari daga "membobi-kawai" perch akan Twitter/X, yin sakaci ko yin watsi da bayanai - kuma ba kawai don maganin Covid ba.
Yawancin bincike na likitanci da ilimin harhada magunguna yana hulɗa da matakan rashin tabbas, wani abu wanda na koya wa ɗalibai na akai-akai kuma ina fatan yawancin masana kimiyyar likitanci sun riga sun sani kuma sun fahimta. Sanarwa in ba haka ba ba za ta zama rashin alhaki da ke fitowa daga kowane masanin kimiyyar likitanci ba, balle ma wanda ke da shaidar Dr. Hotez.
Dr. Hotez ya bayyana rashin tabbas cewa: ivermectin shine "gaba daya mara tasiri"kuma amfani da ivermectin yana wakiltar"anti-kimiyya karya tsafta da sauki"Ba a bayyana su ba a cikin bita na gwaje-gwajen asibiti da yawa da kuma manyan nazarin kididdiga na wallafe-wallafen da aka buga. A gaskiya ma, akwai bayanan da suka ci karo da bayanin Dr. Hotez cewa "Ivermectin ba ya yin komai don taimaka wa mutanen da ke da Covid."
Imanina ne cewa ci gaba da tattara ingantattun bincike na ivermectin zai ci gaba kuma yana nuna babban tasiri ga rigakafin rigakafin cutar Covid-19, bayyanar da wuri, da hanyoyin jiyya da wuri. Kamar ƙwararren masanin kimiyya, ni mai buɗe ido ne kuma a shirye nake in ji ƙwararrun tunani, madadin tunani daga masu zagi na. Ana faɗin haka, Ina da adadi mai yawa na bayanan da ke goyan bayan ra'ayi na.
Martani ga Maganar Dr. Hotez: “Ivermectin ba ya yin wani abu don taimaka wa mutanen da ke da Covid"
Tun da ba a ba ni izinin amsawa akan Twitter/X ba, (ban da gaskiyar cewa ba dandalin da ya dace ba don tattauna cikakkun bayanai game da bayanan gwaji na asibiti) Ina amsawa ta hanyar bita, bincike, da kuma tsayin daka, annotate bibliography.
Ya kamata masu ilimi su karfafa tattaunawa kan batutuwa masu rikitarwa. A wajen shirya gardama, mutum yana buƙatar gabatar da shi duk data samu – ba musamman fifiko binciken daga zaɓaɓɓun "babban suna" mujallolin likitancin gida (wanda ta hanyar su ne sau da yawa nauyi kudi da tsada tallace-tallace daga Big Pharma) - amma halattaccen bayanan asibiti da kimiyya daga duk kafofin.
Na farko, wallafe-wallafe a cikin mujallolin "babban suna" kamar su NEJM da kuma Jama ba nassi mai tsarki ba ne fiye da zargi. Hakanan, akwai ingantaccen bincike da ake gudanarwa a cikin ƙasashen da ba na Amurka ba da/ko kuma ana buga su a cikin ƙananan mujallolin da suka cancanci la'akari. Har ila yau, wadanda suka kashe rayuwarsu a binciken likita za su gaya muku cewa ba -NEJM da kuma wa]Jama, Ƙananan "babban suna" ƙananan, abubuwan lura, da / ko bayanan binciken na ainihi ba kawai sun cancanci la'akari ba, amma cewa waɗannan ƙirar binciken da sakamakon na iya zama sau da yawa fiye da nuna alamun amfani da aminci na miyagun ƙwayoyi.
Binciken Ivermectin na Cochrane bai cika ba
Cochrane's Maris 2024 An ambaci bita na ivermectin a matsayin tushen bayanai don ivermectin ba shi da tasiri. Koyaya, Cochrane kawai yayi la'akari da 11 Randomized Sarrafa Gwaji (RCTs) rufewa 3,409 mahalarta. Don ivermectin, akwai Farashin RCT50 rufe 17,243 mahalarta wanda idan aka yi nazari a hade, yana nuna kwakkwarar shaida don inganci a cikin Covid-19. Gaskiyar cewa Cochrane selectively cire adadi mai yawa na bayanan karatu, yayin da lokaci guda ya haɗa da ƙananan bayanai masu inganci tare da babban rikici na sha'awa da ƙira mai ƙima sosai, ya fi ɗan damuwa. Na bayanin kula, Cochrane kuma bai haɗa dukkan shaidun daga binciken da ya zaɓa ya haɗa da; An rarraba bayanai zuwa ƙananan ƙananan ƙananan ta hanyar sakamako da matsayi na haƙuri, ba tare da wata hanyar da aka yi amfani da ita ba don haɗa duk shaidun daga binciken masu zaman kansu.
Ga alama a gare ni Cochrane ba shine abin da ya kasance ba, kuma ni daya na ji takaici.
data Analysis
Daidaitaccen aikace-aikacen da ma'auni na bayanai da kuma tasirin sa bazuwar meta-bincike a duk nazarin na iya ba da cikakken hoto na tasiri. Ya haɗa da duk bayanan, gami da ƙarancin-ƙasa, gajeriyar lokaci, ƙarancin inganci a ƙarshen-masanin jiyya na farko, yin amfani da maganin azumi ba daidai ba (ivermectin yana da kyau a sha tare da abinci mai mai yawa [2.5x mafi girma] bisa ga Merck kunshin saka).
Ya zuwa yau, akwai jerin rubuce-rubucen rubuce-rubuce 103 waɗanda suka yi nazarin ivermectin. Waɗannan bayanan kuma sun haɗa da 15 medRxiv da/ko rubuce-rubucen da aka riga aka buga, (don mujallun da suka ƙi yin watsi da labarin Big Pharma da/ko mai yuwuwa waɗanda Fadar White House ta ba da umarnin yin katsalandan) da duk binciken da ya nuna tasirin ivermectin tare da wasu takaddun shaida, amma ba a matakin p≤0.05 ba. A bayanin kula: haɗawa tare da keɓance labaran medRxiv/rubutu baya canza gabaɗayan ingantaccen tasirin jiyya na ivermectin.
Wadannan binciken na asibiti kari ne ga ingantaccen ilmin kwayoyin halitta da hanyoyin hada magunguna na yadda ivermectin ke da tasiri wajen hana shigar wasu kwayoyin cuta cikin sel. Don dalilai na kiyaye tsayin wannan takaddar, ba za a tattauna tsarin aikin harhada magunguna anan ba.
Darajar p ≤0.05 yana da mahimmanci, amma ba komai ba ne
Nazarin tare da p-darajar sama da 0.05 har yanzu suna ba da shaida - kawai shaida tare da ƙarancin amincewar 95%. Shi kaɗai, waɗannan karatun na iya ba da tabbaci na ƙididdiga da kansu a kan hasashe mara tushe. Koyaya, suna iya ba da gudummawa ga a meta-bincike, wanda a ciki ake auna su daidai. A cikin bincike, ƙila a haƙiƙa suna haifar da ƙaƙƙarfan shaidar ƙididdiga da ƙarin tabbaci daga haɗar bayanai daga ƙungiyoyin kimiyya masu zaman kansu da yawa. Karamin karatu da na zahiri na zahiri bai kamata a yi watsi da su a matsayin rashin tabbas ba; ko da rahotannin shari'o'i da jerin shari'o'in sun taka muhimmiyar rawa a tarihin bincike na kwayoyin halitta da kuma kimanta lafiyar miyagun ƙwayoyi. A gaskiya ma, waɗannan hanyoyin bayanan sun kasance wani ɓangare na abin da na yi la'akari akai-akai a cikin amincewa da sababbin magunguna da kuma sabunta lakabi a cikin shekaru na a FDA a matsayin ƙwararren lafiyar ƙwayoyi.
RCTs an fi son su a zahiri idan an tsara su da kyau kuma an gudanar da su a hankali, amma zamanin Covid ya fallasa mummunan ra'ayi a cikin irin waɗannan gwaje-gwajen: gami da amma ba'a iyakance ga jinkirin jiyya (kamar yadda Covid-19 tare da kowane maganin rigakafi dole ne a fara da sauri) ka'idojin da aka tsara don gazawa, sauye-sauye na tsakiyar karatu, bincike na son zuciya da gabatarwa, da rashin bayyana gaskiya a cikin bayanai da kuma lokacin fitar da jama'a cikin tuhuma. Ya kamata a kimanta kowane binciken don yuwuwar son zuciya da / ko ruɗani akan cancantar kansa, ko bazuwar ko na lura, babba ko ƙarami.
Manyan RCTs da ake zargin suna samar da Big Pharma-coined-term of "Shaida-Based Medicine ™" da aka buga a cikin "manyan mujallolin" na iya zama mai ban sha'awa sosai, musamman saboda su ne abin da 'yan jarida ke nunawa mafi yawan lokuta, amma likitoci ya kamata su san cewa yana da mahimmanci a bincika hanyoyin da aka yi amfani da su fiye da babban matakin taƙaitaccen bayani da kuma duba ƙarin tushen bayanai.
Wata matsala tare da RCTs ita ce, ba kamar ainihin duniya da nazarin kallo ba, ba kowa ba ne kawai zai iya gudanar da manyan RCTs. Shingayen sun hada da su akai-akai muhimmanci mafi tsada, mai cin lokaci kuma yana buƙatar sadaukarwa, ƙwararrun ma'aikatan tallafi. Waɗannan nau'ikan buƙatun sun hana shiga ta ƙwararrun likitocin da ba su da kuɗi waɗanda ke da ƙananan ayyuka / kayan aiki ko waɗanda ke da buƙatun aiki waɗanda ke da mai da hankali kan alhakin kulawa kai tsaye sabanin binciken asibiti. Duk da yake ana samun tallafin tarayya, suna da gasa sosai kuma suna iya iyakance ga batutuwan da aka jera musamman waɗanda a ƙarshe ana ba da su ga ƙayyadaddun manyan cibiyoyi tare da albarkatun da aka ambata.
Waɗannan manyan cibiyoyin da / ko ma'aikatan su na iya zama haɗa ta wata hanya ko wata zuwa Babban Pharma kudade. Domin samun riba mai yawa na gwajin magunguna na Covid-19, shi iya kai tsaye ko a kaikaice haifar da rikici ko abin ƙarfafawa don nuna rashin tasiri ko aminci ga samfuran jerika masu tsada, sannan kuma suna nuna inganci ga sabon labari, samfuran kasuwanci masu tsada masu tsada. Wannan yanayin ba wai kawai ya shafi jiyya na Covid-19 kamar ivermectin ba, ya shafi adadi mai kyau. dukan binciken likitancin bincike.
A zahiri, ɗimbin ƙarami, ƙarancin tsada waɗanda ba na RCT ba na lura/amfani na zahiri a duk wurare da yawa na iya yin ƙarar ƙara ta hanyar lura cewa dogaro ga wani gwajin mutum ɗaya yana ƙarƙashin yuwuwar ruɗani, kurakurai, son zuciya, har ma da zamba. Saboda haka, haɗe-haɗe daga mahara, da aka tsara da kuma gudanar da ƙarami, ainihin duniya, rahotannin shari'a, jerin shari'o'i, da/ko gwaje-gwajen kallo daga ɗimbin ƙananan wurare, haɗe ta hanyar nazarin meta na iya zama wani lokaci mai nuna ƙarfi fiye da na guda ɗaya ko ƴan manyan gwaji na son zuciya.
A zane daidaita daga a Nature bazawa (a ƙasa) yana misalta yanayin da 4 (hudu) ƙananan karatu waɗanda ɗaiɗaiku zasu iya. ba sun ba da mahimmancin ƙididdiga (watau samun ap>0.05) amma idan aka yi la'akari da su hade, na iya ba da shaida mai ƙarfi tare da mahimmancin ƙididdiga ta hanyar nazarin meta:
Na dabam, waccan littafin ya kuma jaddada yadda yake da mahimmanci ga masana kimiyya da likitoci kada su yi kuskuren ɗauka cewa "marasa mahimmanci" (watau babban karkata daga p≤0.05) yana fassara zuwa "babu tasiri." Muhimmancin ƙididdiga shine kawai ƙididdige ƙididdiga na amincewa da sakamako. Tunanin cewa ƙaramin p-darajar yana nuna cewa ƙiyasin gaskiya ce / gaskiya / inganci / abu-kawai-abu-da-da-matsala kuskure ne. Ƙananan p-darajar RCT (misali) bai faɗi komai ba game da quality na kimanta.
A cikin al'amarin da ke hannun, kuma a taƙaice, bazuwar-sakamakon meta-bincike yana nuna tasirin amfanin asibiti na ivermectin tare da tabbas p<0.00000000001 (wato, ɗaya a cikin sextillion ɗaya) sama da duka karatun ivermectin 103 na Covid-19, da kuma don RCTs kuma don takamaiman sakamako kamar asibiti na mace-mace da lokuta masu dawowa wanda duk yana nuna p <0.0001.
Lokaci Shine Komai…(Lokacin Da Yazo Kan Fara Maganin Cutar Kwayar cuta)
Amfani da kalmar "farkon" a cikin "c19early.com"Shafin yanar gizo muhimmin bayani ne. Yana tunatar da mu yadda mahimmancin lokaci yake idan ya zo ga duk wani maganin rigakafi / maganin rigakafi. wani magungunan rigakafin ƙwayoyin cuta, gami da ciwon sanyi, cututtukan al'aura, mura, ko HIV/AIDS misali.
Gudanar da jinkiri har yanzu yana iya samun fa'idar asibiti, amma ƙasa da haka, dangane da yadda abubuwan da suka makara da ɗaiɗaikun abubuwan da suka haɗa da kwafin ƙwayar cuta, ƙwayar cuta mara kyau, da bambancin/maye gurbi, baya ga yawan alƙaluma, immunologic, da sauran dalilai. Wannan wata mahimmin ra'ayi ce da kowa ya kamata a fagen kantin magani ko likitanci ya koya tun da wuri a makarantarsa, amma duk da haka yana da alama an bar shi a kusan. rabi daga cikin binciken 103 da aka yi akan ivermectin wanda yayi aiki jinkiri or marigayi Magani.
Baya ga jinkirin maganin ivermectin shine jinkirin fitar da sakamakon binciken. Mafi munin misali na iya zama sakamakon PRINCIPLE RCT wanda aka jinkirta sama da kwanaki 800 daga sa ran fitar da binciken. KA'IDAR (littafin littafi da bayani a lamba ta 88 da ke ƙasa) an nuna son kai ga nuna inganci ta hanyar ƙira, aiki, bincike, da bayar da rahoto, gami da ƙarar gudanarwar ivermectin, yet har yanzu ya ƙare yana nuna sakamako mai kyau na ivermectin. A lokacin jinkirin fitar da bayanai, labari, tsada, mai yiwuwa ƙasa da inganci "sakewa" manyan jiyya na Big Pharma kamar molnupiravir da Paxlovid an haɓaka, (kuma an gwada su da placebo maimakon jiyya kamar ivermectin) an sake dubawa, izini, da Fadar White House ta amince. Paxlovid ($ 1,400 a kowace hanya ta magani) da molnupiravir ($ 700 a kowace hanya) kowannensu sun fi ivermectin tsada kusan sau goma (<$100 a kowace hanya). Paxlovid da Fadar White House ta saya ya kashe masu biyan haraji na Amurka fiye da dala biliyan 10.
Don hangen nesa: sama da dala biliyan 9 tanadi daga amfani da ivermectin kadai zai iya saya kusan 36,000. $250,000 Lamborghini Huracans, ko kuma a madadin mu waɗanda dole ne su yi aiki don rayuwa, kusan 300,000 $30,000 Toyota Camry SEs (mafi shaharar samfurin).
Don Covid-19, Akwai Ƙari ga Bayanai fiye da Latsa / Abstract "Sakamakon Topline"
Don cikakken bayani game da bayyana gaskiya, na haɗa da cikakken jerin binciken ivermectin da aka kammala har zuwa yau, tare da yawancin bincike mai kyau da mara kyau a cikin nau'i na bibliography da aka rubuta a ƙarshen wannan labarin don ba da damar masu karatu su ga tushen binciken. Kowace nassoshi 103 sun haɗa da taƙaitaccen taƙaitaccen bayani da hanyar haɗi zuwa dogon bincike a c19 ku.
Tare da bibliography, Ina kuma hada da taƙaitaccen makirci biyu na ivermectin data daga c19 ku akan fa'ida gabaɗaya, da fa'idodin dangi daga prophylaxis, farkon jiyya da kuma marigayi.
A cikin hotunan da aka nuna a sama, da'irar BLUE da aka nuna sune binciken da ke dalla-dalla dalla-dalla binciken binciken ivermectin mai kyau da kuma da'irar RED mara kyau. Akwai bayanan da ba su da kyau, amma tabbataccen binciken ivermectin ya fi su duka a cikin adadin binciken da girman binciken (wanda aka kwatanta da girman da'irar), da kuma kan lokaci da nuni, bisa ga bayanan meta-bincike da aka buga a: c19ivm.org.
RA'AYI: KADA KA daina ko fara shan kowane magani ba tare da fara tattaunawa da likitan kantin magani ko likitan da ka sani kuma ka amince da shi ba.
Littattafan Littafi Mai-Tsarki
1. R. Chahla, L. Medina Ruiz, E. Ortega, M. Morales, F. Barreiro, A. George, C. Mancilla, S. D' Amato, G. Barrenechea, D. Goroso, da M. Peral de Bruno, Babban Jiyya Tare da Ivermectin da Iota-Carrageenan a matsayin Pre-xilli a cikin Ma'aikatan Kula da Lafiya na COVID-19. Janairu 2021, American J. Therapeutics, Juzu'i na 28, Fitowa ta 5, Shafi na e601-e604
234 mai haƙuri ivermectin prophylaxis RCT: 95% ƙananan matsakaici / lokuta masu tsanani (p=0.002) da 84% ƙananan lokuta (p=0.004).
Prophylaxis RCT don ivermectin da iota-carrageenan a Argentina, ma'aikatan kiwon lafiya 117 da aka bi da su tare da ivermectin da iota-carrageenan, da kuma sarrafa 117, suna nuna ƙananan lokuta tare da magani. Babu matsakaici / lokuta masu tsanani tare da jiyya vs. 10 a cikin ƙungiyar kulawa. Akwai lokuta 4 tare da jiyya (duk m) vs. 25 don ƙungiyar kulawa. https://c19p.org/ivercartuc
2. R. Mahmud, M. Rahman, A. Iftikher, K. Ahmed, A. Kabir, SSK Jakaria Been, R. Mohammad Aftab, F. Monayem, I. Shahidul, I. Mohammad Monirul, B. Anindita Das, H. Mohammad Mahfuzul, M. Uzzal, Y. Mohammad Abdullah, M. Hossain, Iverment tare da maganin cutar COVID-19 gwajin bazuwar Oktoba 2020, J. Int. Binciken Likita
MAGANIN FARKO 366 mai haƙuri ivermectin farkon jiyya RCT: 86% ƙananan mace-mace (p=0.25), 57% ƙananan ci gaba (p=0.001), 94% inganta farfadowa (p <0.0001), da 39% inganta ƙwayar cuta (p=0.002).
RCT don ivermectin + doxycycline yana nuna haɓakawa a cikin mace-mace, farfadowa, ci gaba, da maganin virological. Jiyya na 183 da 183 masu kula da marasa lafiya ba tare da mutuwa ba a cikin hannun jiyya vs. 3 a cikin hannun kulawa (ba a haɗa da mutuwar 3 na sarrafawa ba a cikin nazarin wasu sakamakon). Sakamako na iya yin nuni da amfani da ivermectin, doxycycline, da yuwuwar tasirin haɗin gwiwa. A cikin gwajin PRINCIPLE, ba a ga amfanin mace-mace don doxycycline kadai (0.6% mace-mace tare da doxycycline vs. 0.2% iko). https://c19p.org/mahmud
3. V. Desort-Henin, A. Kostova, E. Babiker, A. Caramel, R. Malamut, The SAIVE Trial, Post-Exposure amfani da ivermectin a cikin rigakafin Covid-19: inganci da Safety Results. Janairu 2023, ECCMID 2023
399 mai haƙuri ivermectin pre-exposure prophylaxis RCT: 96% ƙananan lokuta (p <0.0001).
pre-exposure prophylaxis RCT 399 marasa lafiya a Bulgaria suna nuna ƙananan ƙananan shari'o'in Covid-19 tare da ivermectin prophylaxis, kuma ƙananan ƙananan ƙananan ƙwayoyin cuta. Babu wani ɗan takara da ke da alamun bayyanar cututtuka, buƙatar iskar oxygen, ko an kwantar da shi a asibiti. Duk marasa lafiya da ke da Covid-19 an yi musu magani da bitamin C da bitamin D. Wannan gwaji ya sa da Binciken Cochrane bayar da rahoton ingancin ƙididdiga mai mahimmanci don rigakafin, kodayake Cochrane bai bayyana ya yarda da wannan ba tukuna. A halin yanzu akwai 4 prophylaxis RCTs, kuma duka 4 suna nuna ƙimar ƙimar ivermectin. Cochrane ya yi watsi da su ta hanyar zabar kawai don haɗawa da RCTs prophylaxis bayan fallasa, kodayake an haɗa su don binciken paxlovid tare da yawancin marubuta iri ɗaya.. A lokacin babu RCTs bayan fallasa kuma sun san cewa haɗawa da kowane ɗayan 3 pre-exposure prophylaxis RCTs zai nuna tasiri mai mahimmanci. https://c19p.org/desorthenin
4. M. Varnaseri, F. Amini, R. Jamshididan, M. Dargahi, N. Gheibi, S. Abolghasemi, M. Dayer, N. Varnasseri, K. Hoseinynejad, S. Kheradhoosh, P. Nazari, E. Babadi, S. Mousavinezhad, da kuma P. Ebrahimi, a matsayin Potential Anti-COVID-19 Arsenal Gwajin Makafi Biyu Afrilu 2024, Jundishapur J. Kimiyyar Lafiya, Juzu'i na 16, Mas'ala ta 2
MAGANIN LAFIYA 110 mai haƙuri ivermectin marigayi magani RCT: 82% ƙananan samun iska (p=0.02), 83% ƙananan shigar da ICU (p=0.0004), 33% guntun asibiti (p=0.001), da 28% saurin dawowa (p <0.0001).
RCT 110 mai makafi sau biyu matsakaici zuwa matsakaicin marasa lafiya na Covid-19 yana nuna raguwar shigar ICU sosai, gajeriyar asibiti, saurin saurin bayyanar cututtuka, da haɓaka matakan CRP da LDH tare da maganin ivermectin idan aka kwatanta da placebo. Babu wata mace-mace da ta faru a kowane rukuni. Babu wani mummunan al'amura mara kyau. Lura cewa bincike na farko yana annabta tasirin haɗin gwiwa tare da daidaitaccen ka'idar jiyya da aka yi amfani da ita a cikin ƙungiyoyin biyu. https://c19p.org/varnaseri
5. A. Biber, G. Harmelin, D. Lev, L. Ram, A. Shaham, I. Nemet, L. Kliker, O. Erster, M. Mandelboim, da E. Schwartz, Tasirin ivermectin akan nauyin kwayar cutar hoto da kuma al'adar al'ada a farkon jiyya na marasa lafiya marasa asibiti tare da COVID-19 mai sauƙi - Gwajin gwajin gwaji sau biyu. Fabrairu 2021, Int. J. Cututtuka masu Yaduwa
MAGANIN FARKO 89 mai haƙuri ivermectin farkon jiyya RCT: 70% ƙananan asibiti (p=0.34) da 62% ingantacciyar ƙwayar cuta (p=0.02).
RCT makafi sau biyu don marasa lafiya na Covid-19 masu sassaucin ra'ayi a cikin Isra'ila suna nuna raguwa cikin sauri a cikin ƙwayar cuta tare da jiyya, da ƙananan asibiti tare da magani. An kwantar da shi a asibiti 'yan sa'o'i kadan bayan jinya kuma mai haƙuri ya inganta kuma an sallame shi da sauri. Har ila yau, mawallafa suna nazarin yiwuwar al'ada a kwanakin 2-6, tare da 13% tabbatacce a cikin ƙungiyar ivermectin vs. 48% a cikin ƙungiyar kulawa. Babu matsalolin tsaro. An dauki Ivermectin awa daya kafin abinci, yana rage maida hankali. https://c19p.org/biber
6. R. Chahla, L. Ruiz, T. Mena, Y. Brepe, P. Terranova, E. Ortega, G. Barrenechea, D. Goroso, da M. Peral de Bruno, Gwaje-gwajen da ba a tantance ba - Ivermectin yana sake fasalin maganin COVID-19 na marasa lafiya da ke da ƙarancin cuta a cibiyoyin kula da lafiya na farko. Maris 2021, Bincike, Al'umma da Ci gaba, Juzu'i na 11, fitowa ta 8, Shafi na e35511830844
MAGANIN FARKO 254 mai haƙuri ivermectin farkon jiyya RCT: 87% mafi girma fitarwa na asibiti (p=0.004).
Cluster RCT marasa lafiya a Argentina suna nuna saurin murmurewa tare da ivermectin. Babu mace-mace. An ba da marasa lafiya a Tucumán zuwa ƙungiyar ivermectin kuma an ba da marasa lafiya daga San Miguel de Tucumán da Gran San Miguel de Tucumán zuwa ƙungiyar kulawa. Dukkanin cututtuka, kashi na marasa lafiya maza, da shekaru sun kasance mafi girma a cikin ƙungiyar ivermectin, suna fifita ƙungiyar kulawa. https://c19p.org/chahla
7. M. Khan, M. Khan, C. Debnath, P. Nath, M. Mahtab, H. Nabeka, S. Matsuda, da S. Akbar, maganin Ivermectin na iya inganta hasashen marasa lafiya da COVID-19. Satumba 2020, Archivos de Bronconeumología, Juzu'i na 56, Fitowa ta 12, Shafi na 828-830
MAGANIN LAFIYA 248 mai haƙuri ivermectin marigayi binciken magani: 87% ƙananan mace-mace (p=0.02), 89% ƙananan shigar da ICU (p=0.007), 83% ƙananan ci gaba (p=0.0004), da 87% inganta farfadowa (p=0.02).
Marasa lafiya 115 ivermectin na baya da marasa lafiya 133 suna nuna raguwar mutuwa da saurin kamuwa da cuta. Ana iya samun wasu batutuwa masu yuwuwa da martanin marubuta a [sciencedirect.com, sciencedirect.com]. https://c19p.org/khan
8. Z. Aref, S. Bazeed, M. Hassan, A. Hassan, A. Rashad, R. Hassan, da A. Abdelmaksoud, Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray a Rage Babban Numfashi Alamun COVID-19 Yuni 2021, Int. J. Nanomedicine, Juzu'i na 16, Shafi na 4063-4072
MAGANIN FARKO 114 mai haƙuri ivermectin farkon jiyya RCT: 63% inganta farfadowa (p = 0.0001) da 79% inganta ƙwayar cuta (p=0.004).
RCT 114 marasa lafiya a Misira, 57 da aka bi da su tare da ivermectin mucoadhesive nanosuspension intranasal spray, yana nuna murmurewa da sauri da kariya daga kamuwa da cuta tare da magani. Saukewa: NCT04716569. https://c19p.org/aref
9. A. Chowdhury, Nazarin Kwatancen akan Ivermectin-Doxycycline da Hydroxychloroquine-Azithromycin Therapy akan Marasa lafiya COVID-19 Yuli 2020, Eurasian J. Magunguna da Oncology
MAGANIN FARKO 116 mai haƙuri ivermectin farkon jiyya RCT: 81% ƙananan asibiti (p=0.23), 46% inganta farfadowa (p <0.0001), da 81% inganta ƙwayar cuta (p=0.23).
Ƙananan majiyyaci na 116 RCT tare da ƙananan marasa lafiya waɗanda ke kwatanta ivermectin+doxycycline da hydroxychloroquine +AZ, suna nuna ƙananan asibiti, mafi girman ƙwayar cuta, da ƙudurin bayyanar cututtuka da sauri da ƙwayar cuta tare da ivermectin+doxycycline. Matsakaicin farfadowa na tsakiya na bayyanar cututtuka yana da mahimmanci a ƙididdiga tare da jiyya, yayin da wasu matakan ba su kai ga mahimmancin ƙididdiga ba. Umurnai na shan ivermectin a kan komai a ciki, yana rage yawan ƙwayar huhu. https://c19p.org/chowdhury
10. S. Ahmed, M. Karim, A. Ross, M. Hossain, J. Clemens, M. Sumiya, C. Phru, M. Rahman, K. Zaman, J. Somani, R. Yasmin, M. Hasnat, A. Kabir, A. Aziz, da W. Khan, Kwanakin kwana biyar na ivermectin don maganin COVID-19 na iya rage tsawon lokacin rashin lafiya. Disamba 2020, Int. J. Cututtuka masu Yaduwa, Juzu'i na 103, Shafi na 214-216
MAGANIN FARKO 72 marasa lafiya ivermectin farkon jiyya RCT: 85% ingantattun alamun bayyanar cututtuka (p=0.09), 76% ingantacciyar ƙwayar cuta (p=0.03), da 1% guntu asibiti.
Ƙananan masu haƙuri na 72 RCT na ivermectin da ivermectin + doxycycline suna nuna saurin dawowa tare da ivermectin. Ƙungiyar ivermectin + doxycycline tana amfani da a kawai kashi ɗaya na ivermectin vs. 5 allurai yau da kullun don rukunin ivermectin. An yi gwajin PCR ne kawai mako-mako bayan rana ta 7, don haka lokacin asibiti bazai dace da farfadowar bayyanar cututtuka ba. Ƙungiyar Ivermectin: 12mg kowace rana don kwanaki 5 Ivermectin + doxycycline: 12mg ivermectin guda kashi mai zaman kansa ba tare da taro ba, 200mg doxycycline + 100mg tayin kwanaki 4 https://c19p.org/ahmed
11. K. Shimizu, H. Hirata, D. Kabata, N. Tokuhira, M. Koide, A. Ueda, J. Tachino, A. Shintani, A. Uchiyama, Y. Fujino, da H. Ogura, gwamnatin Ivermectin yana da alaƙa da ƙananan rikice-rikice na gastrointestinal da kuma mafi yawan kwanakin da ba su da iska a cikin marasa lafiya da ke fama da COVID-19 bincike Disamba 2021, J. Kamuwa da cutar sankarau
MAGANIN LAFIYA 88 haƙuri ivermectin marigayi binciken magani: 100% ƙananan mace-mace (p=0.001), 48% ƙananan iska (p=0.03), 43% ƙananan shigar da ICU (p=0.06), da 78% ƙananan ci gaba (p=0.03).
A baya-bayan nan 88 marasa lafiya na Covid-19 sun sami iska a cikin Japan, 39 da aka yi musu magani da ivermectin a cikin kwanaki 3 na shigar da su, yana nuna raguwar haɗarin GI da mace-mace, da haɓaka kwanakin da ba su da isasshen iska tare da jiyya. https://c19p.org/shimizu
12. R. Seet, A. Quek, D. Ooi, S. Sengupta, S. Lakshminarasappa, C. Koo, J. So, B. Goh, K. Loh, D. Fisher, H. Teoh, J. Sun, A. Cook, P. Tambyah, da M. Hartman, Kyakkyawan tasiri na maganin poxichloroquine na baki da kuma maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin rigakafi. gwajin bazuwar lakabin buɗaɗɗen Afrilu 2021, Int. J. Cututtuka masu Yaduwa, Juzu'i na 106, Shafi na 314-322
1,236 mai haƙuri ivermectin prophylaxis RCT: 50% ƙananan lokuta (p=0.0009) da 6% ƙananan lokuta (p=0.61).
Prophylaxis RCT a Singapore tare da 3,037 marasa lafiya marasa lafiya, suna nuna ƙananan lokuta masu tsanani, ƙananan alamun bayyanar cututtuka, da ƙananan tabbatarwa na Covid-19 tare da duk jiyya (ivermectin, HCQ, PVP-I, da Zinc + bitamin C) idan aka kwatanta da bitamin C. Tsarin ivermectin ya kasance. low for 42 kwanaki prophylaxis - kawai kashi ɗaya na 200µg/kg, tare da iyakar 12mg. Meta-binciken bitamin C a cikin gwaje-gwaje 6 da suka gabata yana nuna fa'idar 16%, don haka ainihin fa'idar ivermectin, hydroxychloroquine, da PVP-I na iya zama mafi girma. Cluster RCT mai gungu 40. Ba a kwantar da su a asibiti ba kuma babu mace-mace. https://c19p.org/seet
13. S. Lim, C. Hor, K. Tay, A. Mat Jelani, W. Tan, H. Ker, T. Chow, M. Zaid, W. Cheah, H. Lim, K. Khalid, J. Cheng, H. Mohd Unit, N. An, A. Nasruddin, L. Low, S. Khoo, J. Loh. N., King T. Koh, Song Koh N. Lai, S. Chidambaram, K. Peariasamy, W. Hwong, E. Low, M. Pathmanathan, M. Hamzah, Y. Chan, J. Voo, C. Yap, Y. Chan, L. Vun, K. Kong, Y. Lim, Y. Teoh, A. Abdullah, A. Ramadas, C. Wahab, Ismail, N. Lee K. S. Phua, P. Gopalakrishnan, S. Jaya Selan, I. Ampalakan et al., Ingancin Jiyya na Ivermectin akan Ci gaban Cututtuka Tsakanin Manya Tare da Matsakaicin COVID-19 da Matsakaici: I-TECH Randomized Clinical Trial Nuwamba 2021, Jama, Juzu'i na 182, Fitowa ta 4, Shafi na 426
MAGANIN LAFIYA 490 mai haƙuri ivermectin marigayi magani RCT: 69% ƙananan mace-mace (p=0.09), 59% ƙananan iska (p=0.17), 22% ƙananan shigar da ICU (p=0.79), da 31% ƙananan ci gaba (p=0.29).
RCT 490 marigayi mataki (> 65% huhu ya canza radiyon kirji a tushe) marasa lafiya a asibiti a Malaysia, ba tare da nuna bambanci ba. Mutuwar ta kasance 1.2% na ivermectin vs. 4% don sarrafawa. Idan adadin abubuwan faruwa iri ɗaya ya ci gaba, gwajin zai buƙaci ƙara ~ 13% ƙarin marasa lafiya don isa ga mahimmancin ƙididdiga. watau, ta hanyar ci gaba da gwajin na tsawon makonni ~2, akwai yiwuwar sakamakon ya kasance mai mahimmanci ~ 69% raguwa a cikin mace-mace, wanda zai yi daidai da ~ 4 rayuka da aka ceto idan an karbe su a farkon cutar. Rage mace-mace ya yi daidai da sakamakon daga duk gwaji zuwa yau. Duk da yake ba a kai ga ƙima mai mahimmanci tare da ƙayyadadden gwajin ba, nazarin Bayesian ya nuna yiwuwar 97% na ivermectin yana rage mace-mace. Marubuta sun bayyana sakamakon mace-mace a matsayin “kamantan” kuma ba a ambace su a cikin taƙaitaccen bayani ko ƙarshe ba, suna ba da shawara ga babban mai binciken son zuciya tare da zaɓi don hasashe mara kyau.. https://c19p.org/lim
14. W. Shoumann, A. Hegazy, R. Nafae, M. Ragab, S. Samra, D. Ibrahim, T. Al-Mahrouky, da A. Sileem, Amfani da Ivermectin a matsayin Mai yuwuwar Chemoprophylaxis don COVID-19 a Misira: Gwajin Asibiti na Randomized Agusta 2020, J. Binciken Clinical da Bincike
304 mai haƙuri ivermectin prophylaxis RCT: 91% ƙananan lokuta na bayyanar cututtuka (p=0.001) da 93% ƙananan ƙananan lokuta (p=0.002).
Gwajin rigakafin riga-kafi don abokan hulɗar asymptomatic na majinyatan Covid-19, marasa lafiya ivermectin 203 da marasa lafiya 101. 7.4% na lambobin sadarwa sun haɓaka Covid-19 a cikin rukunin ivermectin vs. 58.4% a cikin ƙungiyar kulawa. Ingancin lokuta na alamun bayyanar cututtuka da lokuta masu tsanani suna kama da juna. Ana ba da gyare-gyaren sakamako don lokuta masu alama kawai. Duba kuma: https://c19p.org/shouman
15. N. Okumuş, N. Demirtürk, R. Çetinkaya, R. Güner, İ. Avcı, S. Orhan, P. Konya, B. Şaylan, A. Karalezli, L. Yamanel, B. Kayaaslan, G. Yılmaz, Ü. Savaşçı, F. Eser, da G. Taşkın, Ƙididdigar Inganci da Tsaro na Ƙara Ivermectin zuwa Jiyya a cikin Mummunan Marasa lafiya na COVID-19 Janairu 2021, BMC Cututtuka masu Yaduwa, Juzu'i na 21, Mas'ala ta 1
MAGANIN LAFIYA 60 mai haƙuri ivermectin marigayi magani RCT: 33% ƙananan mace-mace (p=0.55), 43% mafi girma ingantawa (p=0.18), da 80% inganta ƙwayar cuta (p=0.02).
Ƙananan RCT don Covid-19 mai tsanani yana kwatanta ƙari na ivermectin zuwa daidaitattun kulawa (ƙananan kashi HCQ + AZ + favipiravir), tare da jiyya 30 da marasa lafiya 30 na kulawa a Turkiyya, yana nuna ƙananan mace-mace da kuma saurin farfadowa na asibiti. Har ila yau, mawallafa sun bincika kasancewar maye gurbin kwayoyin halitta wanda ke canza ivermectin metabolism, yana yin tsinkaya cewa za a iya amfani da ivermectin lafiya ba tare da lahani mai tsanani a cikin marasa lafiya ba tare da MDR-1/ABCB1 da / ko CYP3A4 maye gurbi ba, kuma suna ba da shawarar kulawa da magani mai dacewa idan ya cancanta lokacin da ba a samuwa ba. https://c19p.org/okumus
16. Ravikirti, R. Roy, C. Pattadar, R. Raj, N. Agarwal, B. Biswas, P. Manjhi, D. Rai, Shyama, A. Kumar, da A. Sarfaraz, Ivermectin a matsayin yuwuwar jiyya don matsakaici zuwa matsakaicin COVID-19: Makafi sau biyu bazuwar gwajin sarrafa placebo Janairu 2021, J. Pharmacy & Pharmaceutical Sciences, Juzu'i na 24, Shafi na 343-350
MAGANIN FARKO 112 mai haƙuri ivermectin farkon magani RCT: 89% ƙananan mace-mace (p=0.12), 79% ƙananan iska (p=0.1), 14% ƙananan shigar da ICU (p=0.8), da 89% mafi girma na asibiti (p=0.12).
RCT tare da marasa lafiya na Covid-112 masu sauƙi da matsakaici a Indiya, suna nuna ƙarancin mace-mace, samun iska, da shigar da ICU, kodayake ba a ƙididdigewa ba saboda ƙarancin adadin abubuwan da suka faru. Babu mace-mace a hannun jiyya (marasa lafiya 19) sabanin 55% (7 na 4) a hannun kulawa. Sakamakon PCR yana da rudani ta hanyar asarar bin diddigi, tare da 23 sun ɓace a cikin rukunin jiyya da 13 a cikin ƙungiyar kulawa, kuma ƙarin mutane 8 a cikin rukunin da aka saki kafin ranar 6. https://c19p.org/ravikirti
17. O. Babalola, C. Bode, A. Ajayi, F. Alakaloko, I. Akase, E. Otrofanowei, O. Salu, W. Adeyemo, A. Ademuyiwa, da S. Omilabu, Ivermectin yana nuna fa'idodin asibiti a cikin matsakaici zuwa matsakaicin COVID19: Bazuwar sarrafa makafi biyu, binciken amsa kashi a Legas Janairu 2021, QJM: Int. J. Magunguna, Juzu'i na 114, Fitowa ta 11, Shafi na 780-788
MAGANIN FARKO 60 mai haƙuri ivermectin farkon jiyya RCT: 64% inganta ƙwayar cuta (p=0.11) da 41% inganta farfadowa (p=0.07).
Ƙananan RCT kwatanta ivermectin 6mg da 12mg q84hr tare da lopinavir/ritonavir, yana nuna tasiri mai mahimmanci da tasiri na ivermectin akan rage lokaci zuwa PCR-. Nazarin ba ya bayar da rahoton mace-mace, asibiti, ci gaba, farfadowa, da dai sauransu. Takardar ta ba da rahoton canji a cikin SpO2 (Figure 3, ∆Spo2), inda aka gani irin wannan cigaba tare da ƙananan p-darajar tare da ivermectin; duk da haka, wannan sakamakon bai daidaita ba kuma akwai manyan bambance-bambance tsakanin kungiyoyi. Musamman, tushen SpO2 yana da ƙasa a cikin ƙungiyar kulawa, yana ba ƙungiyar kulawa ƙarin ɗaki don ingantawa; don haka ainihin amfanin ivermectin zai iya zama ma fi girma fiye da fa'idar da aka nuna a cikin ∆SpO2.. Duba kuma: https://c19p.org/babalola
18. R. Lima-Morales, P. Méndez-Hernández, Y. Flores, P. Osorno-Romero, C. Sancho-Hernández, E. Cuecuecha-Rugerio, A. Nava-Zamora, D. Hernández-Galdamez, D. Romo-Dueñas, da kuma J. Salmerón na multiffektetherapy. azithromycin, montelukast da acetylsalicylic acid don hana asibiti da mutuwa a cikin cututtukan COVID-19 a cikin Tlaxcala, Mexico Fabrairu 2021, Int. J. Cututtuka masu Yaduwa, Juzu'i na 105, Shafi na 598-605
MAGANIN LAFIYA 768 mai haƙuri ivermectin marigayi binciken magani: 78% ƙananan mace-mace (p=0.001), 52% ƙananan iska (p=0.15), 67% ƙananan asibiti (p=0.001), da 59% inganta farfadowa (p=0.001).
Gwajin da ake shirin yi na majinyata 768 na Covid-19 a Mexico, 481 da aka bi da su tare da ivermectin, AZ, montelukast, da aspirin, da kuma 287 masu kula da marasa lafiya tare da jiyya daban-daban, suna nuna raguwar mace-mace da asibiti, kuma mafi murmurewa a cikin kwanaki 14 tare da jiyya. https://c19p.org/limamorales
19. M. Mayer, A. Krolewiecki, A. Ferrero, M. Bocchio, J. Barbero, M. Miguel, A. Paladini, C. Delgado, J. Ojeda, C. Elorza, A. Bertone, P. Fleitas, G. Vera, da M. Kohan, Tsaro da Ingantaccen Shirin Amfani da Babban Dokokin na MEUR Marasa lafiya Satumba 2021, Yankunan Fasaha a Lafiyar Jama'a, Juzu'i na 10
MAGANIN FARKO 21,232 mai haƙuri ivermectin binciken farkon magani: 55% ƙananan mace-mace (p <0.0001) da 66% ƙananan shigar da ICU (p <0.0001).
Marasa lafiya na 21,232 na baya-bayan nan a Argentina, 3,266 an ba da su don maganin ivermectin, yana nuna ƙarancin mace-mace tare da jiyya. An ga fa'idodi mafi girma ga marasa lafiya> 40, kuma an sami amsa mai dogaro da kashi. https://c19p.org/mayer
20. I. De Jesús Ascencio-Montiel, J. Tomás-López, V. Álvarez-Medina, L. Gil-Velázquez, H. Vega-Vega, H. Vargas-Sánchez, M. Cervantes-Ocampo, M. Villasís-Keever, C. González-zuwa, C. González-da kuma C. Rage Hadarin Asibiti/mutuwa a cikin Marasa lafiya na Ambulator tare da COVID-19 Janairu 2022, Taskar bayanai game da Nazarin Lafiya
MAGANIN FARKO 28,048 mai haƙuri ivermectin farkon binciken magani: 59% ƙananan haɗuwa da mace-mace / asibiti (p <0.0001), 15% ƙananan mace-mace (p=0.16), 9% ƙananan iska (p=0.51), da 48% ƙananan asibiti (p <0.0001).
A baya-bayan nan 28,048 na marasa lafiya na Covid+ a Mexico, 7,898 suna karɓar kayan aikin jiyya da suka haɗa da ƙananan allurai ivermectin, AZ, aspirin, da acetaminophen, ƙarancin mace-mace / asibiti ga waɗanda ke karɓar kayan. Isar da kayan aikin magani ya kasance bisa samuwa a cikin sassan likitanci. Rikowa ba a sani ba kuma yana iya zama ƙasa. Ana ba da ingantaccen sakamako don haɗakar mace-mace/ asibiti. https://c19p.org/dejesusascenciomontiel
21. Z. Aref, S. Bazeed, M. Hassan, A. Hassan, A. Ghweil, M. Sayed, A. Rashad, H. Mansour, da A. Abdelmaksoud, Mahimman Matsayin Ivermectin Mucoadhesive Nanosuspension Nasal Spray a Farfadowar Bayan COVID-19 Anosmia Satumba 2022, Kamuwa da Kamuwa da Magunguna, Juzu'i na 15, Shafi na 5483-5494
MAGANIN LAFIYA 96 haƙuri ivermectin dogon Covid RCT: 74% saurin murmurewa (p=0.0005).
96 haƙuri RCT yana nuna saurin ƙuduri na bayan-Covid anosmia tare da ivermectin nanosuspension hanci. https://c19p.org/aref2
22. A. Mohan, P. Tiwari, T. Suri, S. Mittal, A. Patel, A. Jain, T. Velpandian, U. Das, T. Boppana, R. Pandey, S. Shelke, A. Singh, S. Bhatnagar, S. Masih, S. Mahajan, T. Dwivedi, B. Sahoo, S. Pan. K. Madan, V. Hadda, N. Gupta, R. Garg, V. Meena, da R. Guleria, Single-dose oral ivermectin a cikin m da matsakaici COVID-19 (RIVET-COV): cibiyar guda ɗaya bazuwar, gwajin sarrafa wuribo Fabrairu 2021, J. Kamuwa da cutar sankarau, Juzu'i na 27, Fitowa ta 12, Shafi na 1743-1749
MAGANIN FARKO 157 mai haƙuri ivermectin farkon jiyya RCT: 62% inganta farfadowa (p = 0.27) da 24% inganta ƙwayar cuta (p=0.18).
RCT a Indiya tare da marasa lafiya marasa lafiya, kwatanta 24mg ivermectin, 12mg ivermectin, da kuma placebo suna nuna ci gaba mai mahimmanci a cikin farfadowa da kuma matsayi na PCR + (ranar 5 duka makamai, ranar 7 24mg kawai) tare da jiyya, da kuma nuna babban cigaba ga mafi girma hannun hannu. Ragewar ƙwayar cuta ta kwayar cuta ta kasance iri ɗaya a duk makamai - cikakkun ƙima sun kasance ƙasa don ivermectin ta hanyar dogaro da kashi; duk da haka ƙimar asali na ƙungiyoyin ivermectin ya kasance ƙasa, yana barin ƙasa kaɗan don canji. Babu mutuwa ko amfani da iskar injuna. Babu wani mummunan al'amura mara kyau. Ƙididdigar ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙa'idodin ke ba da fifiko ga sakamakon asibiti akan sakamakon PCR. https://c19p.org/mohan
23. R. Faisal, S. Shah, da M. Hussain, Yiwuwar amfani da azithromycin kadai kuma a hade tare da ivermectin wajen yakar alamun COVID-19 Mayu 2021, Kwararren Likitan J., Juzu'i na 28, Fitowa ta 05, Shafi na 737-741
MAGANIN FARKO 100 mai haƙuri ivermectin farkon jiyya RCT: 68% inganta farfadowa (p=0.005).
RCT 100 marasa lafiya a Pakistan, 50 da aka yi musu magani tare da ivermectin, suna nuna saurin murmurewa tare da ivermectin. Duk marasa lafiya sun sami AZ, zinc, bitamin C, bitamin D, da acetaminophen. Ba a bayar da cikakkun bayanai na bazuwar ba. Ba a bayar da rahoton mace-mace ko asibiti ba. https://c19p.org/faisal
24. B. George, M. Moorthy, U. Kulkarni, S. Selvarajan, P. Rupali, D. Christopher, T. Balamugesh, W. Rose, K. Lakshmi, A. Devasia, N. Fouzia, A. Korula, S. Lionel, A. Abraham, da V. Mathews, Single Dose of Ivermectinnts is not Useful with Patiell. Gwajin Sarrafa Bazuwar Buɗaɗɗen Mataki na II B Mayu 2022, Indiya J. Hematology da Zubar jini
MAGANIN LAFIYA 112 mai haƙuri ivermectin marigayi magani RCT: 30% ƙananan mace-mace (p=0.55), 19% farfadowa da sauri (p=0.37), 33% ƙananan ci gaba (p= 0.41), da 33% mafi muni mai saurin kamuwa da cuta (p=0.5).
RCT tare da nau'in 35 guda 24mg, 38 guda ɗaya na 12mg, da kuma 39 daidaitattun kulawa da marasa lafiya marasa lafiya tare da cututtuka na hematological a Indiya, ba tare da nuna bambanci ba. Sakamakon ya kasance mafi kyau ga 24mg vs. 12mg don duk sakamakon bayyanar cututtuka. Sakamakon cirewar ƙwayar cuta ba ya bin bazuwar tare da ƙasa da 50% na marasa lafiya da aka gwada a rana ta 7, kuma ba a samar da ingantaccen sakamako ba. An samu sakamakon kawai 43.8% na marasa lafiya ivermectin da 56.4% na marasa lafiya a ranar 7 kuma maiyuwa ba za a iya kwatanta su ba saboda babban bambanci a cikin adadin marasa lafiyar da aka gwada.. Ƙananan ɗaukar hoto a cikin ƙungiyar ivermectin yana da alaƙa da murmurewa cikin sauri. https://c19p.org/george
25. . Fabrairu 2022, gwaji, Juzu'i na 23, Mas'ala ta 1
MAGANIN FARKO 72 mai haƙuri ivermectin farkon jiyya RCT: 43% inganta farfadowa (p = 0.26) da 5% inganta ƙwayar cuta (p=1).
Ƙananan RCT tare da 72 marasa lafiya marasa lafiya a Tailandia, suna nuna ingantaccen farfadowa tare da ivermectin, ba tare da mahimmancin ƙididdiga ba. Duk marasa lafiya sun murmure kuma babu wani haɓakar kulawa a kowane rukuni. Babu abubuwan da ba su da kyau. https://c19p.org/manomaipiboon
26. H. Hashim, M. Maulood, C. Ali, A. Rasheed, D. Fatak, K. Kabah, A. Abdulamir, Sarrafa gwajin gwaji na asibiti akan amfani da Ivermectin tare da doxycycline don kula da marasa lafiya na COVID-19 a Baghdad, Iraq Oktoba 2020, Iraqi J. Kimiyyar Lafiya
MAGANIN LAFIYA 140 mai haƙuri ivermectin marigayi magani RCT: 92% ƙananan mace-mace (p=0.03), 83% ƙananan ci gaba (p=0.07), da 41% saurin dawowa (p=0.0001).
RCT 70 ivermectin + doxycycline marasa lafiya da 70 masu kula da marasa lafiya suna nuna rage lokaci zuwa farfadowa da rage yawan mace-mace tare da magani. Tun da farko magani ya fi nasara. Don dalilai na ɗabi'a, marasa lafiya masu mahimmanci duk sun kasance a cikin rukunin jiyya. Saukewa: NCT04591600. https://c19p.org/hashim
27. A. Mirahmadizadeh, A. Semati, A. Heiran, M. Ebrahimi, A. Hemmati, M. Karimi, S. Basir, M. Zare, A. Charlys da Costa, M. Zeinali, M. Sargolzaee, da O. Eilami, Ingancin kashi-kashi ɗaya da hana kashi biyu na asibiti a cikin ci gaba a farkon magani na COVID-19. Hannu da yawa, rukunin layi ɗaya bazuwar, makafi biyu, gwaji mai sarrafa wuribo Yuni 2022, Ilimin numfashi
MAGANIN FARKO 261 mai haƙuri ivermectin farkon jiyya RCT: 67% ƙananan iska (p=0.37), 46% ƙananan asibiti (p=0.22), da 39% inganta farfadowa (p=0.27).
RCT tare da 131 24mg ivermectin, 130 12mg ivermectin, da 130 placebo marasa lafiya, suna nuna wani bambanci mai mahimmanci a sakamakon. An ga ƙananan samun iska da asibiti tare da magani, ta hanyar dogara da kashi, amma ba a kai ga kididdiga ba tare da ƙananan abubuwan da suka faru. https://c19p.org/mirahmadizadeh
28. I. Efimenko, S. Nackeeran, S. Jabori, J. Zamora, S. Danker, da D. Singh, Jiyya tare da Ivermectin Yana Haɗe da Rage Mutuwar Mutuwa a cikin Marasa lafiya na COVID-19: Binciken Ƙididdigar Bayanai na Ƙasa Fabrairu 2022, Int. J. Cututtuka masu Yaduwa, Juzu'i na 116, Shafi na S40
SANIN KAI MAGANIN LAFIYA 41,608 mai haƙuri ivermectin marigayi magani propenity madaidaicin binciken: 69% ƙananan mace-mace (p <0.0001).
Marasa lafiya 41,608 na baya-bayan nan a Amurka, 1,072 da aka yi wa ivermectin da 40,536 magani da remdesivir, yana nuna ƙarancin mace-mace tare da jiyya na ivermectin. An gabatar da wannan binciken a wani taro (IMED 2021). An yi bitar abubuwan da aka gabatar da juna. Girman ƙungiyar kulawa / kulawa sun yi daidai da kiyasin adadin asibitocin da suka yi amfani da ivermectin vs. remdesivir. Asibitoci a Amurka sun samu tallafin kudi don amfani da remdesivir. Marubuta sun sanya kansu kan rahoton taron na wannan sakamakon, ba saboda kowane kuskure a cikin bincike ba, amma saboda sun yi imanin ivermectin "ya tabbatar da cewa ba shi da tasiri a cikin gwaji na asibiti." Wannan ba daidai ba ne, yayin da wasu nazarin ba su nuna wani tasiri mai mahimmanci ba, nazarin yana nuna sakamako mai mahimmanci na ƙididdiga don sakamako ɗaya ko fiye (nazarin da ke gaba da kuma na baya, ciki har da RCTs). Ƙaddamar da kai da yanke shawarar ba da kai ga jarida suna ba da ƙarin shaida na rashin nuna son kai ga binciken ivermectin.. https://c19p.org/efimenko
29. S. Mondal, A. Singha, D. Das, S. Neogi, P. Gargari, M. Shah, D. Arjunan, P. Mukhopadhyay, S. Ghosh, J. Chowdhury, S. Chowdhury, Yawaitar COVID-19 kamuwa da cuta da kuma Gano Hadarin Factors tsakanin Asymptomatic Ingancin Ma'aikatan Lafiya a Yammacin Asymptomatic Ma'aikatan Lafiya. Mayu 2021, J. na kungiyar likitocin Indiya
1,470 mai haƙuri na ivermectin prophylaxis binciken: 88% ƙananan lokuta (p=0.006).
Ma'aikatan kiwon lafiya 1,470 na baya-bayan nan a Indiya, suna nuna ƙarancin haɗarin alamun Covid-19 tare da rigakafin ivermectin. https://c19p.org/mondal
30. S. Mourya, A. Thakur, D. Hada, V. Kulshreshtha, Y. Sharma, Nazarin Nazarin Kwatancen Kwatancen Magungunan Magunguna daban-daban guda biyu a cikin Jiyya na Marasa lafiya na Covid 19 a Index Medical College Hospital da Cibiyar Bincike, Indore, Indiya Maris 2021, Int. J. Lafiya da Bincike na asibiti
MAGANIN FARKO 100 mai haƙuri ivermectin binciken farko na jiyya: 89% ingantacciyar kariya ta hoto (p <0.0001).
Marasa lafiya 100 na baya-bayan nan a Indiya tare da 50 da aka bi da su tare da ivermectin, da daidaitattun kulawa ga duk marasa lafiya ciki har da HCQ + AZ, suna nuna mafi girman ƙwayar cuta tare da ivermectin. Matsayin asibiti na asali ya kasance mafi muni a cikin ƙungiyar kulawa. Lokacin gwaji bayan fara jiyya ya fi tsayi a cikin rukunin kulawa (ma'ana kwanaki 7.24 da kwanaki 5.22). https://c19p.org/mourya
31. P. Behera, B. Patro, B. Padhy, P. Mohapatra, S. Bal, P. Chandanshive, R. Mohanty, S. Ravikumar, A. Singh, S. Singh, S. Pentapati, J. Nair, da G. Batmanbane, Prophylactic Role na Ivermectin Syndrome a cikin Mummunar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Cutar ta Coronavirus. Fabrairu 2021, Cureus 13:8
3,346 mai haƙuri ivermectin prophylaxis binciken: 83% ƙananan lokuta (p=0.001).
Nazarin prophylaxis mai zuwa tare da ma'aikatan kiwon lafiya 3,532, 2,199 suna karɓar kashi biyu na ivermectin prophylaxis, yana nuna haɗarin dangi da aka tabbatar da Covid-19 tare da jiyya 0.17 [0.12-0.23] p<0.001. 186 marasa lafiya sun dauka kawai kashi na farko, kuma ba a sami babban bambanci ga wannan rukuni ba. Ƙungiyar guda ta buga wani karamin bincike na baya tare da marasa lafiya 117 ivermectin. Babu wani mummunan al'amura mara kyau. https://c19p.org/behera2
32. M. Alam, R. Murshed, P. Gomes, Z. Masud, S. Saber, M. Chaklader, F. Khanam, M. Hossain, A. Momen, N. Yasmin, R. Alam, A. Sultana, da R. Robin, Ivermectin a matsayin Pre-exposure Prophylaxis for COVID-19 tsakanin Asibitin Kula da Lafiyar da aka Zaɓa a Dhahar. Disamba 2020, Turai J. Kimiyyar Kiwon Lafiya da Lafiya, Juzu'i na 2, Mas'ala ta 6
118 mai haƙuri ivermectin prophylaxis binciken: 91% ƙananan lokuta (p <0.0001).
Rage kashi 91% a cikin shari'o'in Covid-19 tare da ivermectin prophylaxis. Ma'aikatan kiwon lafiya 118 a Bangladesh, 58 suna karɓar ivermectin 12mg kowane wata, yana nuna RR 0.094, p <0.0001. https://c19p.org/alam2
33. P. Behera, B. Patro, A. Singh, P. Chandanshive, RSR, S. Pradhan, S. Pentapati, G. Batmanabane, P. Mohapatra, B. Padhy, S. Bal, S. Singh, da R. Mohanty, Matsayin ivermectin a cikin rigakafin SARS-CoV-2 kamuwa da cuta tsakanin ma'aikatan kiwon lafiya a Indiya. Nuwamba 2020, KUMA KUMA, Juzu'i na 16, fitowa ta 2, Shafi na e0247163
372 mai haƙuri ivermectin prophylaxis binciken: 54% ƙananan lokuta (p=0.0007).
Binciken da aka yi a baya-bayan nan game da maganin rigakafin cutar kanjamau don hydroxychloroquine, ivermectin, da bitamin C tare da ma'aikatan kiwon lafiya 372, yana nuna ƙananan abubuwan da suka faru na Covid-19 ga duk jiyya, tare da ƙimar ƙididdiga ta kai ga ivermectin. Hydroxychloroquine KO 0.56, p = 0.29 Ivermectin KO 0.27, p <0.001 Vitamin C KO 0.82, p = 0.58 https://c19p.org/beherai
34. J. Rajter, M. Sherman, N. Fatteh, F. Vogel, J. Sacks, da J. Rajter, Amfani da Ivermectin yana da alaƙa da ƙananan mace-mace a cikin marasa lafiya na asibiti tare da COVID-19 (binciken ICON) Oktoba 2020, Chest, Juzu'i na 159, Fitowa ta 1, Shafi na 85-92
MAGANIN LAFIYA 280 mai haƙuri ivermectin marigayi magani mai dacewa da ƙimar daidaitaccen binciken: 46% ƙananan mace-mace (p=0.05) da 64% ƙananan iska (p=0.1).
Marasa lafiya na asibiti na 280 na baya-bayan nan suna nuna ƙarancin mace-mace tare da ivermectin (13.3% vs 24.5%), haɓakar haɓakar rashin daidaituwa 0.47 [0.22-0.99], p=0.045. https://c19p.org/rajter
35. J. Morgenstern, J. Redondo, A. Olavarria, I. Rondon, S. Roca, A. De Leon, J. Canela, J. Tavares, M. Minaya, O. Lopez, A. Castillo, A. Placido, R. Cruz, Y. Merette, M. Toribio, da kuma J. Francisco, Iverme-Cod a cikin tsarin Proxis-Code a cikin tsarin Proxis-Code a cikin tsarin SARS-Code-Code. Ma'aikatan Kiwon Lafiya: Maki mai Mahimmanci-Madaidaici Nazari na Ƙungiya na Komawa Afrilu 2021, Cureus
542 mai haƙuri ivermectin prophylaxis prophylaxis prophylaxis madaidaicin ma'aunin binciken: 74% ƙananan lokuta (p=0.008).
Ƙarfafawa ya dace da nazarin prophylaxis na baya-bayan nan na ma'aikatan kiwon lafiya a Jamhuriyar Dominican yana nuna ƙananan lokuta tare da jiyya, kuma babu asibiti tare da jiyya (a kan 2 a cikin ma'auni mai dacewa da ya dace da ƙungiyar kulawa). Abubuwan da aka yi da magani sun kasance mafi yawa a cikin makon farko, tare da shari'ar guda ɗaya kawai a cikin makonni na biyu da na uku, kuma babu ɗaya a cikin mako na huɗu. Babu illa mai tsanani. A cikin bincike na baya-bayan nan, yayin da ƙungiyar kulawa ta dakatar da magani a tsawon lokaci, kariyarsu kuma ta ragu. https://c19p.org/morgenstern2
36. K. Shah Bukhari, A. Asghar, N. Perveen, A. Hayat, S. Mangat, K. Butt, M. Abdullah, T. Fatima, A. Mustafa, da T. Iqbal, Tasirin Ivermectin a cikin COVID-19 Marasa lafiya masu Sauƙi zuwa Matsakaici Cuta Jan 2021, medRxiv
MAGANIN FARKO 86 mai haƙuri ivermectin farkon jiyya RCT: 82% ingantacciyar kariya ta hoto (p <0.0001).
RCT na ƙananan ƙananan marasa lafiya na asibiti tare da 50 ivermectin da 50 marasa lafiya masu kulawa suna nuna mahimmancin ƙwayar cuta mai sauri tare da magani. An rasa marasa lafiya tara a cikin hannun jiyya don biyo baya idan aka kwatanta da 5 a cikin hannun kulawa, wanda zai iya zama wani ɓangare saboda saurin dawowa tare da magani. Babu damuwa lafiya. Ba a bayar da rahoton mace-mace ba. Lambobin da ke cikin Tebur 3 sune adadin marasa lafiya da suka zama mara kyau a wannan ranar, watau, ba tarawa ba. Matsayin kulawa ya haɗa da bitamin C da bitamin D. NCT04392713. https://c19p.org/bukhari
37. G. Espitia-Hernandez, L. Munguia, D. Diaz-Chiguer, R. Lopez-Elizalde, F. Jimenez-Ponce, Effects na Ivermectin-azithromycin-cholecalciferol hade far a kan COVID-19 masu kamuwa da cutar: Tabbacin nazarin ra'ayi Agusta 2020, Binciken Halittu
MAGANIN FARKO 35 mai haƙuri ivermectin binciken farko na jiyya: 70% farfadowa da sauri (p=0.0001) da 97% ingantacciyar kariya ta hoto (p <0.0001).
Ƙananan binciken tare da marasa lafiya 28 da aka yi amfani da su tare da ivermectin + AZ + cholecalciferol da marasa lafiya 7 masu kulawa. Duk marasa lafiya da aka yi wa magani sune PCR- a rana ta 10 yayin da duk marasa lafiya na kulawa sun kasance PCR +. Matsakaicin lokacin bayyanar cututtuka shine kwanaki 3 a cikin ƙungiyar kulawa da kwanaki 10 a cikin ƙungiyar kulawa. https://c19p.org/espitiahernandez
38. J. Merino, V. Borja, O. López, J. Ochoa, E. Clark, L. Petersen, S. Caballero, Ivermectin da rashin daidaituwa na asibiti saboda COVID-19: shaida daga nazarin gwaji-kwakwalwa dangane da sa hannun jama'a a Mexico City Mayu 2021, Preprint
TAMBAYA MAGANIN FARKO 77,381 mai haƙuri ivermectin binciken farkon magani: 74% ƙananan asibiti (p=0.001).
Binciken amfani da birnin Mexico na kayan aikin likitanci na tushen ivermectin, yana nuna ƙarancin asibiti tare da amfani. Marubuta suna amfani da ƙira-ƙira-regression tare da abubuwan lura da suka dace, gami da daidaitawa don shekaru, jima'i, tsananin Covid, da cututtuka. An tantance wannan preprint ta asali mai watsa shiri. Masu bincike sun yi iƙirarin cewa shirin na gwamnati, wanda ya yi amfani da magungunan da aka amince da shi kuma ya ceci mutane sama da 500 daga asibiti, bai dace ba.. A wani bangare kuma sun nuna cewa binciken "sakamakon magani a kan sakamakon cuta" yana waje da iyakokin rukunin yanar gizon su; duk da haka, retroactive tantance takarda saboda wannan dalili bai dace ba. Ana iya samun martanin marubucin (ba a bayar da ta censors ba). nan: Marubuta suna ba da bayanai da lambar don binciken, kuma sakamakon ya kasance tabbatar da kansa. https://c19p.org/merino
39. C. Bernigaud, D. Guillemot, A. Ahmed-Belkacem, L. Grimaldi-Bensouda, A. Lespine, F. Berry, L. Softic, C. Chenost, G. Do-Pham, B. Giraudeau, S. Fourati, da O. Chosidow, Ivermectin fa'ida: daga scabies, misali na COVID-19 Nuwamba 2020, Annals na Dermatology da Venereology, Juzu'i na 147, Fitowa ta 12, Shafi na A194
3,131 mai haƙuri ivermectin prophylaxis binciken: 99% ƙananan mace-mace (p=0.08) da 55% ƙananan lokuta (p=0.01).
Mazauna 69 na gidan kula da Faransanci, matsakaicin shekaru 90, an yi musu magani da ivermectin don barkewar cutar. An yi amfani da mazauna 3,062 a cikin gidaje 45 na kusa da su azaman sarrafawa. Bakwai daga cikin majinyata 69 da aka yi wa jinyar suna da yuwuwar ko wasu Covid-19, ba tare da wasu lokuta masu tsanani ba kuma babu mutuwa. A cikin kwatankwacin gidajen kulawa a gundumar guda, wanda ya dace da shekaru da matakin tattalin arziki, an sami mutuwar 22.6% Covid-19 da 5% mutuwar. https://c19p.org/bernigaud
40. E. Nuwamba 2021, J. Likitan Kwayoyin cuta
MAGANIN LAFIYA 120 haƙuri ivermectin marigayi magani binciken: 75% ƙananan mace-mace (p=0.09), 13% ƙananan samun iska (p=0.2), da 9% tsawon asibiti (p=0.09).
Ƙananan binciken madaidaicin maki mai dacewa a cikin Amurka, yana nuna ƙarancin mace-mace 75% tare da jiyya na ivermectin, ba tare da kai ma'anar ƙididdiga ba, gajeriyar samun iska da lokacin ICU, da tsawon lokacin asibiti. Marubuta sun bar ingantaccen ingantaccen ƙididdiga a cikin samun iska da lokacin ICU daga taƙaitaccen bayani da ƙarshe, kuma sun faɗi daidai cewa babu bambance-bambance. a wasu sakamakon. Marubuta suna da shakku kan sakamakon farko, yana nufin sakamakon farko na mace-mace a cikin yanayi ɗaya, kuma "sakamakon asibiti, wanda aka auna ta adadin intubation, tsawon zaman asibiti, da tsawon lokacin iskar inji"A wani yanayin. Tsawon lokacin asibiti na iya kasancewa wani bangare saboda yawan mace-mace a cikin rukunin kulawa. https://c19p.org/ozer
41. F. Ochoa-Jaramillo, F. Rodriguez-Vega, N. Cardona-Castro, V. Posada-Velez, D. Rojas-Gualdron, H. Contreras-Martinez, A. Romero-Millan, da J. Porras-Mansilla, Clinical inganci da aminci na ivermectin (400g) marasa lafiya tare da marasa lafiya guda 19. gwajin asibiti bazuwar Oktoba 2022, Revista Infection
MAGANIN LAFIYA 75 mai haƙuri ivermectin marigayi magani RCT: 57% ƙananan mace-mace (p=0.35), 34% mafi girma samun iska (p=0.62), da 37% mafi girma shigar ICU (p=0.52).
Farashin 75 sosai marigayi mataki marasa lafiya a Kolombiya, yana nuna babu wani bambanci mai mahimmanci a cikin sakamako tare da kashi ɗaya na 400μg/kg ivermectin. https://c19p.org/ochoajaramillo
42. L. Pierre da F. Christine, Ivermectin da COVID-19 a cikin Gidan Kulawa: Rahoton Case Afrilu 2021, J. Cututtuka masu Yaduwa da Cututtuka, Juzu'i na 7, Mas'ala ta 4
MAGANIN FARKO 25 mai haƙuri ivermectin binciken farkon magani: 70% ƙananan mace-mace (p=0.34) da 55% ƙananan ƙananan lokuta (p=0.11).
Ƙananan nazarin bazuwar (zaɓin haƙuri) tare da marasa lafiya 25 PCR + a cikin gidan kulawa da aka ba da ivermectin, wanda 10 ya zaɓi a yi masa magani. Matsakaicin shekarun shine 83.5 a cikin ƙungiyar kulawa da 81.8 a cikin ƙungiyar kulawa. An sami raguwar mace-mace da ƙananan lokuta masu tsanani tare da magani. https://c19p.org/loue
43. L. Kerr, F. Cadegiani, F. Baldi, R. Lobo, W. Assagra, F. Proença, P. Kory, J. Hibberd, da J. Chamie-Quintero, Ivermectin Prophylaxis Amfani da COVID-19: Babban Birni, Mai yiwuwa, Nazarin Dubawa na 223,128spen Mahimmanci ta Amfani da XNUMXspen Mahimmanci Dec 2021, Cureus
159,561 mai haƙuri ivermectin prophylaxis prophylaxis propensity propensity score matching: 70% ƙananan mace-mace (p <0.0001), 67% ƙananan asibiti (p <0.0001), da 44% ƙananan lokuta (p <0.0001).
Makin da ya dace da majinyata 220,517 na baya-bayan nan a Brazil, 133,051 suna shan ivermectin a matsayin wani ɓangare na shirin rigakafi na birni, yana nuna ƙarancin asibiti da mace-mace tare da jiyya. Ana gabatar da ƙarin sakamako a cikin gabatarwar bidiyo na mintuna 90 FLCCC ta shirya anan, ciki har da ingantaccen inganci tare da bincike bisa ga rashin daidaituwa / amfani na yau da kullum, da kuma dangantaka mai karfi da amsa kashi. https://c19p.org/kerr
44. E. Osati, G. Shayo, T. Nagu, R. Sangeda, C. Moshiro, L. Vumilia, L. Samwel, P. Mhame, M. Nkya, D. Rainer, M. John, C. Mbije, G. Nyaisonga, K. Kilonzo, M. Nicholaus, J. Seni, A. Munga, N. Ramas Was, A. Munga, N. Ramas S. A. M. Shekalaghe, da A. Makubi, Bayyanar cututtuka da mace-mace tsakanin marasa lafiya na COVID-19 da ke asibiti a Tanzaniya, 2021-2022. Yuli 2023, medRxiv
MAGANIN LAFIYA 1,387 mai haƙuri ivermectin marigayi magani binciken: 32% ƙananan mace-mace (p=0.02).
A baya bayan nan 1,387 da ke asibiti PCR sun tabbatar da marasa lafiya na Covid-19 a Tanzaniya, suna nuna ƙarancin mace-mace tare da maganin ivermectin tare da maganin steroid a multivariable bincike. https://c19p.org/osati
45. H. Elalfy, T. Besheer, A. El-Mesery, A. El-Gilany, M. Soliman, A. Alhawarey, M. Alegezy, T. Elhadidy, A. Hewidy, H. Zaghloul, M. Neamatallah, D. Raafat, W. El-Emshaty, N. Abo El-Kheir, na Exanzo, da M. Ribavirin da Ivermectin da ƙarin zinc (nazarin MANS.NRIZ) akan kawar da ƙarancin COVID-1 Fabrairu 2021, J. Med. Virol., Juzu'i na 93, Fitowa ta 5, Shafi na 3176-3183
MAGANIN FARKO 113 mai haƙuri ivermectin binciken farko na jiyya: 87% ingantacciyar kariya ta hoto (p <0.0001).
Gwajin sarrafa bazuwar bazuwar tare da marasa lafiya masu sauƙi 62 da farkon matsakaici tare da jiyya a gida tare da ivermectin + nitazoxanide + ribavirin + zinc, yana nuna saurin kawar da kwayar cutar hoto. https://c19p.org/elalfy
46. Huvemek et al., Kovid-19 - Huvemek® Phase 2 gwaji na asibiti Maris 2021, Huvemek, Sanarwar Jarida
MAGANIN LAFIYA 100 mai haƙuri ivermectin marigayi magani RCT: 32% haɓaka mafi girma (p=0.28).
Multicenter makafi biyu RCT tare da 100 marasa lafiya a asibiti a Bulgaria yana nuna saurin kamuwa da kamuwa da cuta, haɓakar asibiti mafi girma, da ingantattun alamomin halitta tare da jiyya. An bayar da rahoton iyakataccen bayanai a halin yanzu. Ba a sami mummunan aukuwa ba. https://c19p.org/petkov
47. V. Spoorthi, S. Sasank, Utility na Ivermectin da Doxycycline hade don maganin SARSCoV-2 Nuwamba 2020, IAIM, 2020, 177-182
MAGANIN LAFIYA 100 mai haƙuri ivermectin marigayi binciken jiyya: 21% saurin dawowa (p=0.03) da 16% guntun asibiti (p=0.01).
Gwajin gwaji na haƙuri 100 na ivermectin + doxycycline yana nuna raguwar lokaci zuwa ƙudurin alama da ɗan gajeren zaman asibiti tare da jiyya. https://c19p.org/spoorthi
48. M. Rezai, F. Ahangarkani, A. Hill, L. Ellis, M. Mirchandani, A. Davoudi, G. Eslami, F. Roozbeh, F. Babamahmoodi, N. Rouhani, A. Alikhani, N. Najafi, R. Ghasemian, H. Mehravaran, A. Hajialibaefar, M. Najavad, M. Najavad, M. Rahimzadeh, M. Saeedi, R. Alizadeh-Navai, M. Moosazadeh, S. Saeedi, S. Razavi-Amoli, S. Rezai, F. Rostami-Maskopaee, F. Hosseinzadeh, F. Movahedi, J. Markowitz, da kuma R. Valadan, Ba tare da Ƙaddamarwa ba CUTAR COVID 19; Sakamako na Bazuwar Guda Biyu, Makafi Biyu, Gwaje-gwajen Asibiti Mai Sarrafa Wuri Yuni 2022, Frontiers a Magunguna, Juzu'i na 9
MAGANIN LAFIYA 609 mai haƙuri ivermectin marigayi magani RCT: 31% ƙananan mace-mace (p=0.36), 50% ƙananan iska (p=0.07), 16% ƙananan shigar da ICU (p=0.47), da 11% tsawon asibiti (p=0.009).
RCT 609 marasa lafiya a Iran. Sakamakon da aka ruwaito ya bambanta sosai da sakamakon da aka ƙayyade. An iyakance adadin a a matsakaicin 30mg na 75+kg, wanda ke haifar da rashin daidaituwa ga marasa lafiya a cikin haɗari mafi girma. Kusan duk marasa lafiya sun karɓi remdesivir (wanda ke da mahimman bayanan aminci mai zaman kansa), yawancin marasa lafiya sun karbi famotidine da bitamin C, kuma yawancin marasa lafiya sun karbi bitamin D, metformin, da zinc, iyakance dakin don ingantawa. 32% na marasa lafiya sun ɓace don bin diddigin. Duk sakamako mara kyau shine keta yarjejeniya kuma ba a jera su a cikin ƙa'idar ba, gami da sabon labari na "farfadowar dangi". Marubuta sun haɗa da wani mai bincike da aka kama akan bidiyo yana yarda cewa ƙarshe akan ivermectin bincike ya rinjayi mai ba da kuɗi. https://c19p.org/rezai2
49. T. Siripongboonsitti, K. Tawinprai, P. Avirutnan, K. Jitobaom, da P. Auewarakul, Gwaji Mai Rarraba Don Tantance Haɓakar Ciwon Kwayar cuta ta Haɗin Favipiravir/Ivermectin/Niclosamide a cikin Matsakaici-zuwa-Matsakaici COVID-19 Adult Panti (FINCOV) Maris 2024, J. Kamuwa da Lafiyar Jama'a, Juzu'i na 17, Fitowa ta 5, Shafi na 897-905
MAGANIN FARKO 60 mai haƙuri ivermectin farkon jiyya RCT: 39% inganta farfadowa (p = 0.19) da 6% inganta ƙwayar cuta (p=0.75).
RCT 60 ƙananan marasa lafiya marasa lafiya, matsakaicin shekaru 31, tare da Covid-19 mai sauƙi zuwa matsakaici ba tare da nuna wani bambance-bambance ba tare da haɗin favipiravir/ivermectin/niclosamide idan aka kwatanta da favipiravir kadai. Akwai iyakataccen ɗaki don haɓakawa tare da kusan babu ci gaba kuma babu asibiti, shigar ICU, ƙarin oxygen, ko mace-mace. Ƙungiyar haɗin gwiwar ta nuna mahimmancin ingantaccen ma'aunin sikelin analog na gani don tari, hanci mai gudu, da gudawa daga ranar 3. Mawallafa sun lura cewa " WHO-CPS sun ragu sosai a tsakanin FPV / IVM / NCL vs FPV kadai a ranar 10"; duk da haka ba za a iya ƙayyade matakin haɓaka ba bisa ga ƙimar da aka ruwaito. Mawallafa sun bayyana cewa "Dukkanin bayanan da aka samar ko aka bincikar su yayin wannan binciken an haɗa su a cikin wannan labarin da aka buga," wanda ba daidai ba - kawai an buga ƙididdiga na taƙaitaccen bayani. Rijistar gwaji ta bayyana cewa ba za a samar da bayanai ba. Wannan yana haifar da damuwa, musamman saboda yawancin rashin daidaituwa a cikin bayanan da aka buga: https://c19p.org/siripongboonsitti6
50. S. Budhiraja, A. Soni, V. Jha, A. Indrayan, A. Dewan, O. Singh, Y. Singh, I. Chugh, V. Arora, R. Pande, A. Ansari, da S. Jha, Bayanan Clinical na Farko na 1000 COVID-19 da aka yarda da su a Asibitocin Kula da Lafiya na Indiya da Mahimmancin Halin su. Nov 2020, medRxiv
MAGANIN LAFIYA 976 mai haƙuri ivermectin marigayi magani binciken: 99% ƙananan mace-mace (p=0.04).
Marasa lafiya na asibiti na 976 na baya-bayan nan tare da 34 da aka bi da su tare da ivermectin suna nuna ƙarancin mace-mace tare da ivermectin a cikin sakamakon da ba a daidaita ba. https://c19p.org/budhirajai
51. J. Llenas-García, A. Del Pozo, A. Talaya, N. Roig-Sánchez, N. Poveda Ruiz, C. Devesa García, E. Borrajo Brunete, I. González Cuello, A. Lucas Dato, M. Navarro, da P. Wikman-Jorgensen, Iver Incteed da kuma Iverme Incteed Taimakon Numfashi a cikin COVID-19 ciwon huhu: Makin Ƙarfafawa-Mai Daidaita Nazarin Komawa. Mayu 2023, Useswayoyin cuta, Juzu'i na 15, Fitowa ta 5, Shafi na 1138
MAGANIN LAFIYA 192 mai haƙuri ivermectin marigayi nazarin magani: 17% ƙananan mace-mace (p = 0.82), 18% ƙananan buƙatu don maganin oxygen (p = 0.37), 23% ƙananan ci gaba (p = 0.52), da 4% mafi girma ICU shigar (p = 0.92).
Marasa lafiya 96 na baya-bayan nan suna karɓar a kashi ɗaya na 200 μg/kg ivermectin (Adadin da bai dace ba don strongyloides ko Covid) da 96 madaidaitan sarrafawa, suna nuna babu wani bambanci mai mahimmanci a cikin sakamako. Marubuta sun lura cewa wannan na iya kasancewa saboda ƙarancin adadin da aka yi amfani da shi, don haka jinkirin jinkiri da ƙananan kashi sun ba da gudummawa ga waɗannan binciken. https://c19p.org/llenasgarcia
52. S. Baguma, C. Okot, N. Onira, P. Apiyo, D. Acullu, P. Layet, J. Oloya, D. Ochula, P. Atim, P. Olwedo, F. Pebolo, F. Oyat, J. Oola, J. Aloyo, E. Ikoona, da D. Kitara, Halayen Majinyatan Yankin Arewa na COVID-19 da ake kula da su a asibitin Guguwar Uganda giciye binciken Dec 2021, Dandalin Bincike
MAGANIN LAFIYA 481 mai haƙuri ivermectin marigayi magani binciken: 97% ƙananan mace-mace (p=0.31).
Marasa lafiya na Covid+ na baya-bayan nan da ke asibiti a Uganda, ba su nuna wani bambanci mai mahimmanci a cikin mace-mace tare da ivermectin; duk da haka, 7 kawai daga cikin 481 marasa lafiya sun sami ivermectin. https://c19p.org/baguma
53. W. Schilling, P. Jittamala, J. Watson, M. Ekkapongpisit, T. Siripoon, T. Ngamprasertchai, V. Luvira, S. Pongwilai, C. Cruz, J. Callery, S. Boyd, V. Kruabkontho, T. Ngernseng, J. Tubrakson, M. P. Hanboonkunupakarn, B. Hanboonkunupakarn, S. Sookprome, K. Poovorawan, J. Thaipadungpanit, S. Blacksell, M. Imwong, J. Tarning, W. Taylor, V. Chotivanich, C. Sangketchon, W. Ruksakul, K. Chotivanich, S. Tekrip, M. Tekrip, S. Tekrip, M. Tekrip, M. Tekrip, M. Tekrip, S. Tekrip, M. Tekrip, D. Day, W. Piyaphanee, W. Phumratanaprapin, da N. White, Pharmacometrics na babban kashi ivermectin a farkon COVID-19: buɗaɗɗen lakabin, bazuwar, gwajin dandamali na daidaitawa (PLATCOV) Yuli 2022, eLife, Juzu'i na 12
MAGANIN FARKO 90 mai haƙuri ivermectin farkon jiyya RCT: 86% ƙananan ci gaba (p=0.24) da 9% mafi muni mai saurin kamuwa da cuta (p=0.36).
Babban rikici mai ban sha'awa RCT tare da ƙirar da aka inganta don sakamako mara kyau: marasa lafiya masu ƙarancin haɗari, babban rigakafi na yanzu, canji na baya-bayan nan don ware marasa lafiya mafi kusantar amfana. Babu wani bambanci mai mahimmanci a cikin cirewar ƙwayar cuta a tsakanin marasa lafiya marasa lafiya tare da babban nauyin ƙwayar cuta a asali. Duk abubuwan ci gaba guda 3 sun faru a hannun kulawa - asibiti ɗaya da lokuta biyu na rhabdomyolysis masu alaƙa da Covid-19. Marasa lafiya a cikin makamai biyu sun kawar da kwayar cutar da sauri tare da kawar da kwayar cutar rabin rayuwar sa'o'i 21.1 vs. 19.2 hours, wanda zai iya kasancewa a wani bangare saboda riga-kafin rigakafi. Tare da saurin kawar da ƙwayoyin cuta da marasa lafiya masu ƙarancin haɗari, kamuwa da cuta ba shi da yuwuwar yaduwa zuwa sauran kyallen takarda. Maganin tsari ba shi da amfani, kuma yana da ɗan lokaci don isa ga ma'aunin warkewa kafin a dawo da kai. Ana gudanar da jiyya kai tsaye zuwa sashin numfashi, tare da wasu bayanan da ke nuna cewa na iya zama mafi inganci ga Covid-19. https://c19p.org/schilling
54. K. Abbas, S. Muhammad, da S. Ding, Tasirin Ivermectin akan Rage Alamun Cutar Kwayar cuta a cikin Marasa lafiya masu Mutuwar COVID-19 Disamba 2021, Indiya J. Kimiyyar Magunguna, Mujalladi na 84, Fitowa ta S1
MAGANIN FARKO 202 mai haƙuri ivermectin farkon jiyya RCT: 41% ƙananan ci gaba (p=0.54) da 36% inganta farfadowa (p=0.04).
RCT 99 ivermectin da 103 suna kula da marasa lafiya marasa lafiya a kasar Sin, har zuwa kwanaki 7 daga farkon bayyanar cututtuka, suna nuna ci gaba mai mahimmanci a farfadowa tare da jiyya, da kuma ingantawa marasa mahimmanci a lokacin dawowa da lalacewa. Marubuta sun zaɓi ƙimar p-darajar don farfadowa wanda ke nuna mahimmancin ƙididdiga. Ana ba da bayanai kaɗan akan marasa lafiya (shekaru, jinsi, da matsayin inshora kawai). Teburin, rubutu, da taƙaitaccen bayani suna nuna nau'ikan lambobi daban-daban guda uku. Teburin da taƙaitaccen bayani suna nuna nau'ikan lokacin dawowa daban-daban guda biyu. Ƙirar ta ƙunshi rabon haɗari wanda ba ya cikin rubutu, kuma ba a ba da rahoton hanyoyin ƙididdiga ba. Idan aka yi la'akari da keɓan zaɓi na ƙididdiga mai mahimmanci p-darajar, lambobi daban-daban guda uku don wannan sakamakon, da sauran rashin daidaituwa, bayanan da ke cikin wannan binciken ba ya zama abin dogaro sosai. An cire marasa lafiya> 50. https://c19p.org/abbas2
55. T. Wada, M. Hibino, H. Aono, S. Kyoda, Y. Iwadate, E. Shishido, K. Ikeda, N. Kinoshita, Y. Matsuda, S. Otani, R. Kameda, K. Matoba, M. Nonaka, M. Maeda, Y. Kumagai, J. Ako, M. Shigiri, M. Shichiri, K. Iwamura, K. Katayama, T. Miyatsuka, Y. Orihashi, da K. Yamaoka, Inganci da aminci na ivermectin guda ɗaya a cikin COVID-19 mai sauƙi zuwa matsakaici: makafi biyu, bazuwar, gwajin wuribo-sarrafawa CORVETTE-01 Mayu 2023, Gaba a Magunguna, Juzu'i na 10
MAGANIN LAFIYA 214 mai haƙuri ivermectin marigayi magani RCT: 19% ƙananan ci gaba (p=0.46), 14% mafi girma bukatar maganin oxygen (p=0.46), 23% mafi muni (p=0.61), da 60% inganta farfadowa (p=0.17).
Late jiyya (6.6 kwanaki bayan farawa / PCR +) RCT tare da 221 low-hadari (babu mace-mace) Covid-19 marasa lafiya a Japan, nuna babu wani gagarumin bambanci a cikin hoto ko bidiyo mai zagaya yanar gizo da sauri tare da guda ɗaya na ivermectin a karkashin azumi. Marubuta sun lura cewa an yi amfani da kashi ɗaya na 200 μg/kg a ƙarƙashin azumi kamar yadda aka yarda a Japan, kuma hakan sosai karancin kashi, shan rana guda, da gudanar da azumi (~ sau 2.5 rage yawan ƙwayar plasma) iyakance amfani, kuma wannan binciken tare da ƙarin sakamako masu kyau gabaɗaya ana amfani da mafi girman kashi ko adadin kwanaki da yawa. Ba a bayar da cikakkun bayanai game da gwajin PCR ba amma jinkirin sharewa a cikin ƙananan ƙarancin jama'a yana nuna babban taro / ƙimar lokaci wanda ƙila ba zai wakilci daidai ga kowane raguwa a cikin kwafin ƙwayar cuta mai iya kwafi ba. Wani erratum yana lura da rikici na sha'awa ga mai bita wanda ya kasance a Ma'aikacin Merck. https://c19p.org/wada
56. Y. Thairu, O. Babalola, A. Ajayi, Y. Ndanusa, J. Ogedengbe, da OO, Kwatanta Ivermectin da Non Ivermectin Based Regimen for COVID-19 a Abuja: Tasiri kan Cire Cutar, Kwanaki-zuwa-fitarwa da Mutuwa Fabrairu 2022, J. Pharmaceutical Research Int., Shafi na 1-19
MAGANIN LAFIYA 87 mai haƙuri ivermectin marigayi magani mai dacewa daidai binciken: 88% ƙananan mace-mace (p=0.12), 55% mafi girma sallamar asibiti (p=0.0001), da 95% ingantacciyar kariya ta hoto (p=0.001).
A baya-bayan nan majiyyata 87 a Najeriya, 61 sun yi jinyar ivermectin, suna nuna raguwar mace-mace, saurin murmurewa, da saurin kamuwa da kwayar cutar kwayar cutar ta ivermectin. Duk marasa lafiya sun karbi zinc da bitamin C. An ga tasirin synergistic don kawar da kwayar cutar yayin da An hada ivermectin da remdesivir. Dangane da rikicewa ta lokaci (bambanci mai yuwuwa a cikin bambancin Covid), tare da marasa lafiya ivermectin daga Afrilu-Yuni 2021, da marasa lafiya marasa ivermectin daga Satumba-Nuwamba 2021. https://c19p.org/thairu
57. N. Rezk, A. Elsayed Sileem, D. Gad, da A. Khalil, miRNA-223-3p, miRNA-2909 da Bayyanar Cytokines a cikin marasa lafiya na COVID-19 da aka yi wa Ivermectin Oktoba 2021, Jami'ar Zagazig Medical J., Juzu'i na 0, Fitowa ta 0, Shafi na 0-0
MAGANIN LAFIYA 320 mai haƙuri ivermectin marigayi binciken jiyya: 56% ƙananan ci gaba (p=0.06), 33% ingantaccen farfadowa (p=0.27), da 27% saurin kamuwa da kwayar cutar hoto (p=0.01).
Masu zuwa 320 marasa lafiya na Covid-19+ masu matsakaicin asibiti a Masar, 160 sun yi maganin ivermectin, suna nuna ƙarancin mace-mace, ingantaccen murmurewa, da rage maganganun cytokine tare da jiyya. An yi wa duk marasa lafiya magani da hydroxychloroquine. https://c19p.org/rezk
58. R. Qadeer, S. Kashif, D. Kumar, M. Mehmmood, J. Lal, da F. Agusta 2022, Pakistan J. Kimiyyar Kiwon Lafiya da Lafiya, juzu'i na 16, fitowa ta 8, Shafi na 24-26
MAGANIN LAFIYA 210 mai haƙuri ivermectin marigayi magani binciken: 58% inganta ƙwayar cuta (p <0.0001).
Nazarin samfurin dacewa mai yiwuwa na marasa lafiya 210 da suka yi daidai da shekarun asibiti na Covid-19, yana nuna saurin kamuwa da kamuwa da cuta tare da ivermectin. Ba a bayar da bayanan tushen kowane rukuni ba. https://c19p.org/qadeer
59. S. Samajdar, S. Mukherjee, T. Mandal, J. Paul, Ivermectin da Hydroxychloroquine don Chemo-Prophylaxis na COVID-19: Binciken Tambayoyi na Hane-hane da Tsara Ayyuka na Likitoci vi-a-vis Sakamako Nov 2021, J. Associationungiyar Likitocin Indiya
309 mai haƙuri ivermectin prophylaxis binciken: 80% ƙananan lokuta (p <0.0001).
Binciken likitoci a Indiya tare da 164 ivermectin prophylaxis, 129 hydroxychloroquine prophylaxis, da marasa lafiya 81, yana nuna raguwar cututtukan Covid-19 tare da jiyya. Cikakkun bayanai na ƙungiyoyin jiyya da kulawa da ba a bayar da ma'anar lokuta ba, kuma sakamakon yana ƙarƙashin son zuciya. Marubuta kuma suna ba da rahoto game da rigakafin al'umma amma hada ivermectin/ Sakamakon hydroxychloroquine. https://c19p.org/samajdar
60. M. Mukarram, Amfani da Ivermectin Haɗe da Rage Tsawon Cutar Covid-19 na Fabrairu a cikin Saitin Al'umma. Disamba 2020, Int. J. Nazarin Clinical & Rahoton Harka Lafiya, Juzu'i na 13, Mas'ala ta 4
MAGANIN FARKO 90 mai haƙuri ivermectin farkon binciken magani: 92% inganta farfadowa (p=0.04).
Marasa lafiya 95 na baya-bayan nan a cikin Pakistan tare da tuhuma mai ƙarfi na asibiti na Covid-19 (ba a sami gwajin ko'ina ba), tare da marasa lafiya 40 da aka yi musu magani tare da ivermectin, yana nuna ɗan gajeren lokacin rashin lafiya tare da jiyya. Yawancin marasa lafiya kuma sun sami HCQ, AZ, zinc, da aspirin. Marubuta sun lura cewa akwai alaƙar jinkirin jinkiri. https://c19p.org/ghauri
61. M. Helwig da A. Maia, Maganin rigakafin COVID-19? Ƙananan abin da ya faru da ke hade da prophylactic gudanarwa na Ivermectin Nuwamba 2020, Int. J. Magungunan rigakafi, Juzu'i na 57, Fitowa ta 1, Shafi na 106248
Ivermectin prophylaxis binciken: 78% ƙananan lokuta (p=0.02).
Binciken shari'o'in Covid-19 vs. yawan amfani da ivermectin don rigakafin kamuwa da cuta yana nunawa. rage yawan kamuwa da Covid-19 lokuta. https://c19p.org/hellwig
62. C. Chaccour, A. Casellas, A. Blanco-Di Matteo, I. Pineda, A. Fernandez-Montero, P. Ruiz-Castillo, M. Richardson, M. Rodríguez-Mateos, C. Jordán-Iborra, J. Brew, F. Carmona-Torre, M. Gabaso, J, E.ira Laónba, E.ira Laónba G. Moncunill, J. Yuste, J. Del Pozo, N. Rabinovich, V. Schöning, F. Hammann, G. Reina, B. Sadaba, da kuma M. Fernández-Alonso, Sakamakon magani na farko tare da ivermectin akan nauyin hoto mai hoto, bayyanar cututtuka da amsa mai ban dariya a marasa lafiya tare da marasa lafiya marasa ƙarfi, gwajin gwaji na biyu, gwajin gwaji na COVID-19, gwajin gwaji na biyu. Disamba 2020, Magungunan Magunguna, Juzu'i na 32, Shafi na 100720
MAGANIN FARKO 24 mai haƙuri ivermectin farkon jiyya RCT: 96% ingantattun alamun bayyanar cututtuka (p=0.05), 95% ingantacciyar ƙwayar cuta (p=0.01), da 8% ingantacciyar kariya ta hoto (p=1).
Ƙananan RCT don farkon jiyya na Covid-19 mai sauƙi a cikin marasa lafiya masu ƙarancin haɗari, tare da 12 400mcg / kg marasa lafiya na ivermectin guda ɗaya da marasa lafiya 12, suna nunawa. rage girman nauyin ƙwayar cuta da sauri da haɓaka alamun tare da ivermectin. https://c19p.org/chaccour
63. S. Abd-Elsalam, R. Noor, R. Badawi, M. Khalaf, E. Esmail, S. Soliman, M. Abd El Ghafar, M. Elbahnasawy, E. Moustafa, S. Hassany, M. Medhat, H. Ramadan, M. Eldeen, M. Alboraie, A. Cordie, da G. Esdy, Evaver of the Clinical S. Jiyya na COVID-19: Nazarin Bazuwar Sarrafa Yuni 2021, J. Likitan Kwayoyin cuta, Juzu'i na 93, Fitowa ta 10, Shafi na 5833-5838
MAGANIN LAFIYA 164 mai haƙuri ivermectin marigayi magani RCT: 20% guntu asibiti (p=0.09).
RCT 164 marasa lafiya a asibiti a Masar suna nuna ƙananan mace-mace da gajeriyar asibiti, amma ba tare da mahimmancin ƙididdiga ba. Babu wani mummunan tasiri. Marubuta sun ba da shawarar ƙananan sashi na iya haifar da ƙarancin inganci fiye da sauran gwaje-gwaje kuma suna ba da shawarar ƙara yawan adadin a gwaji na gaba. Ba a kayyade lokaci daga farkon alamun ba. The An sake yin rajistar gwaji kuma ranar fara daukar ma'aikata a cikin rajistar gwaji (Yuni 2020) ya bambanta da takarda (Maris 2020). Don sauran abubuwan da ke damun ku duba [kanlinlin..wiley.com]. https://c19p.org/abdelsalam3
64. E. López-Medina, P. López, I. Hurtado, D. Dávalos, O. Ramirez, E. Martínez, J. Díazgranados, J. Oñate, H. Chavarriaga, S. Herrera, B. Parra, G. Libreros, R. Jaramillo, A. Avendaño, da Rio, D. Tores I. Caicedo, Tasirin Ivermectin akan Lokaci don Gyaran Alamomin Tsakanin Manya Tare da Mummunar COVID-19: Gwajin Nazari na Asibiti Maris 2021, Jama, Juzu'i na 325, Fitowa ta 14, Shafi na 1426
MAGANIN FARKO 398 mai haƙuri ivermectin farkon jiyya RCT: 61% ƙananan ci gaba (p=0.11) da 15% inganta farfadowa (p=0.53).
Binciken waya tushen RCT tare da marasa lafiya marasa lafiya, 200 ivermectin da kulawar 198, suna nuna ƙananan mace-mace, ƙananan ci gaba da cututtuka, ƙananan haɓakar jiyya, da kuma saurin ƙuduri na bayyanar cututtuka tare da magani, ba tare da kai ma'anar kididdiga ba. Marubuta sun gano sakamakon wannan gwaji kadai ba sa goyan bayan amfani da ivermectin. Duk da haka tasirin duk yana da kyau, musamman ga sakamako masu tsanani waɗanda ba za su iya kaiwa ga mahimmancin ƙididdiga tare da ƙananan adadin abubuwan da ke faruwa a cikin ƙananan ƙananan ƙananan mutane ba. Budaddiyar wasiƙa, wacce ke da sa hannun> 100 likitoci, kammala wannan binciken yana da nakasu mai rauni ana iya samunsa a jamaletter.com. Tare da ƙananan ƙananan ƙananan marasa lafiya, akwai ƙananan wuri don ingantawa tare da magani mai mahimmanci - 59/57% (IVM / sarrafawa) ya murmure a cikin kwanaki 2 na farko zuwa ko dai "babu alamun cutar" ko "ba a asibiti ba kuma babu iyakance ayyukan;" 73/69% a cikin kwanaki 5. Kasa da 3% na duk marasa lafiya sun taɓa lalacewa. An canza sakamakon farko a tsakiyar gwaji. https://c19p.org/lopezmedina
65. M. Munir, A. Khan, da T. Khan, Halayen Cututtuka na Clinical da Hanyoyin Jiyya Haɗe da Mutuwa tsakanin Marasa lafiya COVID-19 a Punjab, Pakistan Afrilu 2023, Kiwon Lafiya, juzu'i na 11, fitowa ta 8, Shafi na 1192
MAGANIN LAFIYA 1,000 marasa lafiya ivermectin marigayi magani binciken: 48% ƙananan mace-mace (p=0.13).
A baya-bayan nan marasa lafiya 1,000 na asibiti na Covid-19 a Pakistan, suna nuna ƙarancin mace-mace tare da ivermectin ba tare da ma'anar ƙididdiga ba. https://c19p.org/munir
66. A. Zeeshan Khan Chachar, K. Ahmad Khan, M. Asif, K. Tanveer, A. Khaqan, da R. Basri, Tasirin Ivermectin a cikin majinyatan SARS-CoV-2/COVID-19 Satumba 2020, Int. J. Kimiyya-35, Juzu'i na 9, Fitowa ta 09, Shafi na 31-35
MAGANIN LAFIYA 50 mai haƙuri ivermectin marigayi magani RCT: 10% inganta farfadowa (p=0.5).
Ƙananan RCT tare da 25 ivermectin da 25 masu kula da marasa lafiya, ba su sami babban bambanci a farfadowa a ranar 7 ba. https://c19p.org/chachar
67. C. Podder, N. Chowdhury, M. Sina, da W. Haque, Sakamako na ivermectin da aka bi da su marasa sauƙi zuwa matsakaicin COVID-19: cibiyar guda ɗaya, alamar buɗaɗɗen, binciken sarrafa bazuwar. Satumba 2020, IMC J. Med. Kimiyya, Juzu'i na 14, Fitowa ta 2, Shafi na 11-18
MAGANIN LAFIYA 62 mai haƙuri ivermectin marigayi magani RCT: 16% saurin dawowa (p=0.34).
Ƙananan RCT tare da marasa lafiya na ivermectin 32 da marasa lafiya na 30. Ma'anar lokacin dawowa bayan yin rajista a cikin hannun hannu shine 5.31 ± 2.48 kwanaki vs. 6.33 ± 4.23 kwanakin a cikin hannun kulawa, p> 0.05. Sakamakon PCR mara kyau bai bambanta sosai tsakanin sarrafawa da makamai ba, p>0.05. Ba a bayyana abin da sakamakon ya kasance saboda abstract da Table 5 sun canza sakamakon. https://c19p.org/podder
68. H. Tanioka, S. Tanioka, da K. Kaga, Me yasa COVID-19 ba ya yaɗuwa a Afirka: Ta yaya Ivermectin ke shafar ta? Maris 2021, medRxiv
Nazarin prophylaxis na Ivermectin: 88% ƙananan mace-mace (p=0.002).
Binciken da aka yi na baya-bayan nan na kasashe 31 na onchocerciasis-endemic ta hanyar amfani da maganin al'umma tare da ivermectin da kasashe 22 da ba su da cutar a Afirka, wanda ke nuna raguwar mace-mace ga kowane mutum a cikin kasashen da ke amfani da ivermectin. https://c19p.org/tanioka
69. D. Camprubí, A. Almuedo-Riera, H. Martí-Soler, A. Soriano, J. Hurtado, C. Subirà, B. Grau-Pujol, A. Krolewiecki, da J. Muñoz, Rashin ingancin daidaitattun allurai na ivermectin a cikin marasa lafiya na COVID-19 mai tsanani. Nuwamba 2020, KUMA KUMA, Juzu'i na 15, fitowa ta 11, Shafi na e0242184
MAGANIN LAFIYA 26 mai haƙuri ivermectin marigayi nazarin magani: 40% ƙananan samun iska (p=0.67), 33% ƙananan shigar da ICU (p=1), 33% mafi muni (p=1), da 25% mafi muni mai saurin kamuwa da cuta (p=1).
Ƙananan marasa lafiya na 26 na baya-bayan nan game da jinkirin jinkiri tare da ivermectin 200 μg/kg, tsaka-tsakin kwanaki 12 bayan bayyanar cututtuka, ba tare da nuna bambanci ba. Marubuta sun ba da shawarar adadin ya yi ƙasa da ƙasa kuma suna ba da shawarar kimanta mafi girma allurai. Duk marasa lafiya sun karɓi hydroxychloroquine wanda zai iya rage yuwuwar fa'idar ƙara ivermectin. https://c19p.org/camprubi
70. F. Gorial, S. Mashhadani, H. Sayaly, B. Dakhil, M. AlMashhadani, A. Aljabory, H. Abbas, M. Ghanim, da J. Rasheed, Tasirin Ivermectin a matsayin ƙarin farfadowa a cikin Gudanar da COVID-19 (Gwajin gwaji) Yuli 2020, medRxiv
MAGANIN LAFIYA 87 haƙuri ivermectin marigayi magani binciken: 42% guntun asibiti (p <0.0001).
Ƙananan gwaji na marasa lafiya na asibiti tare da 16 na 87 marasa lafiya da ake kula da su tare da ivermectin, yana nuna a ƙananan ma'anar zaman asibiti tare da ivermectin: 7.62 vs. 13.22 days, p=0.00005. Zero na marasa lafiya na ivermectin 16 sun mutu vs. 2 na marasa lafiya na 71. https://c19p.org/gorial
71. H. Pott-Junior, M. Paoliello, A. Miguel, A. Da Cunha, C. De Melo Freire, F. Neves, L. Da Silva de Av'o, M. Roscani, S. Dos Santos, da S. Chacha, Amfani da ivermectin a cikin maganin Covid-19: gwajin gwaji. Maris 2021, Rahoton Toxicology, Juzu'i na 8, Shafi na 505-510
MAGANIN LAFIYA 31 mai haƙuri ivermectin marigayi magani RCT: 85% ƙananan samun iska (p=0.25), 85% ƙananan shigar da ICU (p=0.25), da 1% ingantacciyar kariya ta hoto (p=1).
Ƙananan RCT tare da 4 masu kula da marasa lafiya da 28 ivermectin marasa lafiya sun rabu a cikin matakan 3 daban-daban na sashi, suna nuna ƙananan (marasa ƙididdiga) shigar da ICU tare da magani. Marubuta sun ba da shawarar cewa ivermectin na SARS-CoV-2 ba shi da lafiya kuma yana rage alamun cutar da ƙwayar cuta, kuma tasirin antiviral yana da alaƙa da dogaro da kashi. Ja da baya/tabbaci: Ga dukkan alamu an tantance wannan takarda bisa bukatar editan da ya kafa mujallar. An ambaci bita na waje amma ba a bayar da ita ba, kuma babu amsa daga marubutan zuwa rukunin C19, ko nunin cewa an sanar da marubutan. Ƙarshe a cikin wannan binciken yana iyakance saboda ƙananan girman; duk da haka, har yanzu an yi la'akari da shi a cikin mahallin cikakken binciken. https://c19p.org/pottjunior
72. F. Cadegiani, A. Goren, C. Wambier, da J. McCoy, Farkon COVID-19 Therapy tare da azithromycin da nitazoxanide, ivermectin ko hydroxychloroquine a cikin Saitunan Marassa lafiya Ingantacciyar sakamako na COVID-19 idan aka kwatanta da Sanannun sakamako a cikin marasa lafiya da ba a kula da su ba. Nuwamba 2020, Sabbin ƙwayoyin cuta da Sabbin cututtuka, Juzu'i na 43, Shafi na 100915
MAGANIN FARKO 24 marasa lafiya ivermectin binciken farko na magani: 94% ƙananan samun iska (p=0.005) da 98% ƙananan asibiti (p <0.0001).
Kwatanta hydroxychloroquine, nitazoxanide, da ivermectin suna nuna tasiri iri ɗaya don jimlar sakamakon asibiti a cikin Covid-19 lokacin da aka yi amfani da shi kafin kwanaki bakwai na alamun cutar, kuma mafi girman gaske idan aka kwatanta da yawan mutanen da ba a kula da su ba na Covid-19, har ma ga waɗancan sakamakon ba su tasiri tasirin placebo ba, aƙalla lokacin da aka haɗa su tare da azithromycin, da bitamin C, D da zinc a mafi yawan lokuta. 585 marasa lafiya tare da jinkirin jinkiri na tsawon kwanaki 2.9. Babu asibiti, iskar injina, ko mace-mace tare da jiyya. Ƙungiyar kulawa ta 1 ta kasance ƙungiyar da aka dawo da ita na marasa lafiya marasa lafiya na yawan jama'a. https://c19p.org/cadegianii
73. S. Hazan, S. Dave, A. Gunaratne, S. Dolai, R. Clancy, P. McCullough, da T. Borody, Tasirin maganin multidrug na tushen ivermectin a cikin matsanancin hypoxic, marasa lafiya na COVID-19. Yuli 2021, Microbiology na gaba, Juzu'i na 17, Fitowa ta 5, Shafi na 339-350
MAGANIN LAFIYA 24 mai haƙuri ivermectin marigayi binciken magani: 86% ƙananan mace-mace (p=0.04) da 93% ƙananan asibiti (p=0.001).
Ƙananan nazarin marasa lafiya 24 a jere a cikin mummunan yanayi (kwanaki 9 bayan bayyanar cututtuka, yana nufin SpO2 87.4) ta yin amfani da haɗin gwiwa tare da ivermectin, doxycycline, zinc, bitamin D, da bitamin C, wanda ke nuna rashin mutuwa ko asibiti tare da magani. Marasa lafiya biyu sun ki yarda da magani kuma duka sun mutu. Wannan binciken yana amfani da hannu mai sarrafa roba. https://c19p.org/hazan
74. J. Beltran Gonzalez. Guerra, inganci da amincin Ivermectin da Hydroxychloroquine a cikin Marasa lafiya masu tsananin COVID-19: Gwajin Sarrafa Bazuwar Fabrairu 2021, Rahoton Cututtuka masu Yaduwa, Juzu'i na 14, Fitowa ta 2, Shafi na 160-168
MAGANIN LAFIYA 73 mai haƙuri ivermectin marigayi magani RCT: 14% ƙananan mace-mace (p = 1), 9% ƙananan ci gaba (p = 1), 37% ƙananan asibiti (p = 0.71), da 20% tsawon asibiti (p = 0.43).
RCT marigayi mataki mai tsanani yanayin, high-comorbidity asibiti marasa lafiya a Mexico tare da 36 low-dose ivermectin da 37 kula da marasa lafiya. rashin samun bambance-bambance masu mahimmanci. An taso da tambayoyi game da wannan binciken da farkon ƙarshen binciken da kuma dakatar da jiyya, saboda ƙididdiga na asibiti ya nuna raguwar adadin masu mutuwa (~ 75%) a lokacin binciken.: Duba https://c19p.org/beltrangonzalez
75. . Disamba 2021, Binciken Bincike a cikin Magungunan Magunguna da Magunguna, Shafi na 100101
MAGANIN LAFIYA 444 mai haƙuri ivermectin marigayi magani binciken: 64% ƙananan mace-mace (p=0.09).
Marasa lafiya na asibiti 444 na baya-bayan nan a Pakistan, suna nuna ƙarancin mace-mace tare da jiyya na ivermectin a cikin sakamakon da ba a daidaita su ba, bai kai ga mahimmancin ƙididdiga ba. An yi amfani da Ivermectin mafi yawa tare da marasa lafiya a cikin mawuyacin hali, yanayin ƙarshen zamani. Adadin ya kasance daga 12mg zuwa 36mg har zuwa kwanaki bakwai. https://c19p.org/mustafa
76. C. Héctor, H. Roberto, A. Psaltis, da C. Veronica, Nazarin Tasiri da Tsaro na Topical Ivermectin + Iota-Carrageenan a cikin Prophylaxis da COVID-19 a cikin Ma'aikatan Lafiya Nuwamba 2020, J. Binciken Halittu da Bincike na Asibiti, Juzu'i na 2, Mas'ala ta 1
1,195 mai haƙuri ivermectin prophylaxis binciken: 100% ƙananan lokuta (p <0.0001).
Nazarin prophylaxis ta amfani da ivermectin da iota-carrageenan yana nuna 0 na lokuta 788 daga ma'aikatan kiwon lafiya da aka kula da su, idan aka kwatanta da 237 na 407 iko. Duba a nan don tattauna batutuwan da suka shafi wannan gwaji. https://c19p.org/carvalloprep
77. G. Reis, E. Silva, D. Silva, L. Thabane, A. Milagres, T. Ferreira, C. Dos Santos, V. Campos, A. Nogueira, A. De Almeida, E. Callegari, A. Neto, L. Savassi, M. Simplicio, L. Ribeiro, R. Oliveira, O. Harari, Spi. C. Guo, K. Rowland-Yeo, G. Guyatt, D. Boulware, C. Rayner, da E. Mills, Tasirin Jiyya na Farko tare da Ivermectin tsakanin Marasa lafiya da Covid-19 Agusta 2021, New England J. Medicine
MAGANIN FARKO 1,358 mai haƙuri ivermectin farkon jiyya RCT: yayin da aka gabatar da shi azaman mara kyau, babban mai binciken ya ba da rahoton a cikin imel a cikin imel a ranar 3 ga Afrilu, 2022 cewa "Akwai bayyanannen sigina cewa IVM yana aiki a cikin marasa lafiya na COVID." Gwaji tare Ivermectin: bayanan da ba za a iya yiwuwa ba, batutuwa masu mahimmanci, ɓarna makanta, gazawar bazuwar, keta alkawarin bayanai, take hakki. Shari’ar canza daga ciki har da marasa lafiya da aka yi wa allurar zuwa ban da su a ranar 21 ga Maris, 2021. Abubuwan da aka bayyana ta rikice-rikice sun haɗa da Pfizer. Wani marubuci ya yi iƙirarin cewa rahoton ivermectin yana aiki kamar yadda "disinformation.” Duba kuma: Tambayoyi 10 don Masu Binciken Gwaji tare, Da kuma FDA ta bayyana damuwa game da yadda ake gudanar da gwaji tare, Haɗuwa da Sauran Masu Gudanarwa. Atari a: https://c19p.org/togetherivm
78. T. Ahsan, B. Rani, R. Siddiqui, G. D'Souza, R. Memon, I. Lutfi, OI Hasan, R. Javed, F. Khan, da M. Hassan, Bambance-bambancen Clinical, Halaye, da Sakamako Tsakanin Marasa lafiya COVID-19: Binciken Jerin Cases a Asibitin Kula da Manyan Makarantu a Karachi, Pakistan Afrilu 2021, Cureus
MAGANIN LAFIYA 165 mai haƙuri ivermectin marigayi magani binciken: 50% ƙananan mace-mace (p=0.03).
Komawa 165 an riga an kwantar da marasa lafiya (marigayi magani). a Pakistan yana nuna ƙananan mace-mace marasa daidaituwa tare da haɗin ivermectin da maganin doxycycline. Ba a bayar da cikakkun bayanai na ƙungiyar ivermectin idan aka kwatanta da sauran marasa lafiya; duk da haka an ba da ivermectin ga irin wannan adadin marasa lafiya a cikin ƙananan, matsakaici, da kuma masu tsanani / ƙungiyoyi masu mahimmanci (34.5%, 29.1%, da 36.4%), yana nuna cewa maganin ivermectin bai dogara da tsanani ba. https://c19p.org/ahsan
79. H. Carvallo, Amfanin Taken Ivermectin da Carrageenan don Hana Yaɗuwar Covid 19 (IVERCAR) Oktoba 2020, NCT04425850
229 mai haƙuri ivermectin prophylaxis binciken: 96% ƙananan lokuta (p <0.0001).
Nazarin prophylaxis ta amfani da ivermectin da carrageenan suna nuna 0 na lokuta 131 daga ma'aikatan kiwon lafiya da aka kula da su, idan aka kwatanta da 11 na kulawar 98. Tasirin yana iya zama da farko saboda ivermectin - marubucin daga baya ya ruwaito cewa carrageenan ba lallai ba ne. https://c19p.org/carvalloprep2
80. H. Carvallo, H. Roberto, Aminci da Ingantaccen Haɗin Amfani da Ivermectin, Dexamethasone, Enoxaparin da Aspirin a kan COVID-19 Protocol IDEA Satumba 2020, J. Gwajin asibiti
MAGANIN FARKO 46 marasa lafiya ivermectin binciken farko na jiyya: 85% ƙananan mace-mace (p=0.08).
Gwajin da za a yi na ivermectin, dexamethasone, enoxaparin, da aspirin, da ke nuna rashin asibiti don lokuta masu laushi, da ƙananan mace-mace ga masu matsakaici/masu tsanani. https://c19p.org/carvallo
81. S. Bhatnagar, A. Elavarasi, H. Raju Sagiraju, R. Garg, B. Ratre, P. Sirohiya, N. Gupta, R. Garg, A. Pandit, S. Vig, R. Singh, B. Kumar, V. Meena, N. Wig, S. Mittal, S. Pahuja R. K. Madan, D. R. Gupta, A. Vidyarthi, R. Chaudhry, A. Das, L. Wundavalli, A. Singh, S. Singh, S. Kumar, M. Pandey, A. Mishra, da kuma K. Matharoo, Siffofin Clinical, Demography, da kuma tsinkaya sakamakon kamuwa da cutar SARS-CoV-2 a asibitin kulawa na manyan makarantu a Indiya: A cohor Agusta 2021, Lung Indiya, Juzu'i na 39, Fitowa ta 1, Shafi na 16
MAGANIN LAFIYA 1,758 mai haƙuri ivermectin marigayi magani binciken: 20% ƙananan mace-mace (p=0.12).
A baya-bayan nan 2,017 marasa lafiya na asibiti a Indiya, suna nuna ƙananan mace-mace tare da maganin ivermectin a cikin sakamakon da ba a daidaita ba. Ba a bayar da cikakkun bayanai na rukuni ba kuma wannan sakamakon yana da rudani ta hanyar nuni. https://c19p.org/elavarasi
82. . Oktoba 2020, medRxiv
MAGANIN LAFIYA 2,833 mai haƙuri ivermectin marigayi magani binciken: 17% ƙananan mace-mace (p=0.01).
Retrospective database binciken na 5,683 marasa lafiya, 692 samu HCQ/CQ+AZ, 200 samu HCQ/CQ, 203 samu ivermectin, 1,600 samu AZ, 358 samu ivermectin+AZ, da kuma 2,630 samu daidaitattun kulawa. Wannan binciken ya haɗa da duk wanda ke da lambobin ICD-10 Covid-19 wanda ya haɗa da marasa lafiya na PCR+ masu asymptomatic; Don haka yawancin marasa lafiya a cikin rukunin kulawa suna iya asymptomatic dangane da SARS-CoV-2, amma a asibiti saboda wani dalili.. Ga waɗanda ke da alamun Covid-19, akwai kuma yuwuwa gagarumin rudani ta hanyar nuni. A cikin wannan binciken duk magunguna suna nuna yawan mace-mace a rana ta 30, wanda ya yi daidai da asymptomatic (na Covid-19) ko marasa lafiya marasa lafiya sun zama ruwan dare a cikin rukunin kulawa. Kaplan Meier masu lankwasa sun nuna cewa ƙungiyoyin masu jiyya sun kasance cikin mawuyacin hali, kuma bayan kusan rana 35 rayuwa ta zama mafi kyau tare da ivermectin.. https://c19p.org/sotobecerrai
83. Ravikirti, A. Ranjan, R. Porel. Afrilu 2022, Dandalin Bincike
MAGANIN LAFIYA 965 mai haƙuri ivermectin marigayi magani binciken: 3% ƙananan mace-mace (p=0.82).
Matsalolin 965 na baya-bayan nan (44% mai tsanani, 27% ICU) marasa lafiya a asibiti a Indiya, suna nuna babu wani bambanci mai mahimmanci tare da maganin ivermectin. Gabaɗaya mace-mace ya yi yawa, yana nuna jinkirin jinkiri. Matsakaicin daidaitacce mara nauyi ba zai iya yin tasiri sosai tare da irin waɗannan marasa lafiya na ƙarshen zamani ba. An cire marasa lafiya 210 saboda sallama da wuri, wanda zai iya kasancewa marasa lafiya tare da farkon farawa wanda zai iya amfana da ivermectin. Haɗin shekarun yana da ban mamaki ba tare da raguwar shekaru ba ga 71% na marasa lafiya> 45. Ƙila ƙila ba za a iya dogaro da lambobi ba, misali, ƙidayar cututtukan zuciya da/ko kashi na IVM sun bayyana ba daidai ba. Ba a bayar da cikakkun bayanai na gyare-gyare ba; ana iya samun matsananciyar ruɗani ta shekaru a cikin> ƙungiyoyin 45 waɗanda ke ɗauke da yawancin marasa lafiya, ban da rikicewa ta nuni. https://c19p.org/ravikirti2
84. S. Roy, S. Samajdar, S. Tripathi, S. Mukherjee, da K. Bhattacharjee, Sakamako na Matsalolin Jiyya daban-daban a cikin Marasa lafiya COVID-19 marasa lafiya a cikin Clinic OPD guda ɗaya na West Bengal: Nazarin Nazari Maris 2021, medRxiv
MAGANIN FARKO 29 mai haƙuri ivermectin binciken farkon magani: 6% saurin dawowa (p=0.87).
Binciken bayanan baya-bayan nan na marasa lafiya na Covid-56 masu sauƙi 19, duk waɗanda aka yi musu magani tare da bitamin C, bitamin D, da zinc, kwatanta ivermectin + doxycycline (n=14), AZ (n=13), hydroxychloroquine (n=14), da daidaitattun kulawa (n=15), gano cewa duk ƙungiyoyi suna murmurewa da sauri, kuma babu wani gagarumin bambanci tsakanin ƙungiyoyin. Dangane da ƙayyadaddun ƙayyadaddun bayanai na binciken bayanai, ƙanƙanta kaɗan, da ƙayyadaddun kimantawa na marasa lafiya. https://c19p.org/roy
85. T. Borody, R. Clancy, Magungunan Haɗuwa Don COVID-19 Dangane da Ivermectin a cikin Yawan Jama'ar Australiya Oktoba 2021, Labari na Wurin gwaji
MAGANIN FARKO 600 mai haƙuri ivermectin binciken farkon magani: 92% ƙananan mace-mace (p=0.03) da 93% ƙananan asibiti (p <0.0001).
Marasa lafiya na PCR 600 na baya-bayan nan a Ostiraliya sun yi maganin ivermectin, zinc, da doxycycline, suna nuna ƙarancin mace-mace da asibiti tare da jiyya. Wannan gwajin yana amfani da ƙungiyar sarrafa roba, kuma rahoton farko yana ba da cikakkun bayanai kaɗan. Musamman ma, fa'idodin sun haɗa da ɗaukar ma'aikata marasa son rai (marasa lafiya ba sa barin idan sun ji suna buƙatar magani kuma ba sa son haɗarin placebo), gwaji yana da rahusa, akwai ƙarancin jinkiri a cikin jiyya, kuma ana iya yin gwaji a inda bai dace ba don baiwa marasa lafiya placebo. https://c19p.org/borody
86. J. Vallejos, Ivermectina da wakilai de salud da IVERCOR COVID19 Dec 2020, IVERCOR PREP, Sakamako na Farko
875 mai haƙuri ivermectin prophylaxis binciken: 73% ƙananan lokuta (p <0.0001).
Rahoton kan ivermectin prophylaxis a wani asibiti a Argentina yana nuna ƙananan lokuta ga ma'aikatan kiwon lafiya suna shan ivermectin. An buga sakamakon a cikin manema labarai kuma an buga gabatarwa a kan layi; duk da haka babu bugu na yau da kullun. Ana tsammanin waɗannan sakamakon za su sami fifikon bugu saboda tasirin da aka annabta akan cutar da kuma tabbatar da binciken rigakafin da ya gabata. Rashin bugu na yau da kullun yana nuna rashin son kai ga wallafawa wanda zai iya kasancewa saboda siyasa a wurin marubutan. Lura cewa wannan binciken prophylaxis ya bambanta da gwajin jiyya na farko na Vallejos. https://c19p.org/vallejos
87. S. Szente Fonseca, A. De Queiroz Sousa, A. Wolkoff, M. Moreira, B. Pinto, C. Valente Takeda, E. Rebouças, A. Vasconcellos Abdon, A. Nascimento, da H. Risch, Hadarin Asibiti ga Ma'aikatan Jihohin Covid-19 da Aka Yi Magance da Magungunan Magunguna daban-daban a Brazil. Oktoba 2020, Maganin Tafiya da Cututtuka masu Yaduwa, Juzu'i na 38, Shafi na 101906
MAGANIN FARKO 717 mai haƙuri ivermectin binciken farkon magani: 14% asibiti mafi girma (p=0.53).
Marasa lafiya 717 na baya-bayan nan a Brazil suna nuna OR 1.17 [0.72-1.90] don ivermectin. Wannan takarda ta mayar da hankali kan hydroxychloroquine; Ba a bayar da adadin abubuwan da suka faru na ivermectin ba. Tare da mahimmancin alaƙa tsakanin masu canji da aka yi amfani da su, gami da zoba a cikin takardar sayan jiyya da yawa waɗanda ke nuna inganci kaɗai, da iyakataccen bayanai don girman samfurin, samfurin da aka yi amfani da shi anan yana iya zama mara kyau saboda multicollinearity https://c19p.org/fonsecai
88. G. Hayward, L. Yu, P. Little, O. Gbinigie, M. Shanyinde, V. Harris, J. Dorward, B. Saville, N. Berry, P. Evans, N. Thomas, M. Patel, D. Richards, O. Hecke, M. Detry, C. Saunders, M. Fitzgerald, J. Latimer Allengbu, J. Robinson, C. Robinson, J. Latimer Allengbu, C. Grabey, S. De Lusignan, F. Hobbs, da C. Butler, Ivermectin don COVID-19 a cikin manya a cikin al'umma (PRINCIPLE): buɗaɗɗen, bazuwar, sarrafawa, gwajin dandamali na daidaitawa na sakamakon gajere da tsayin lokaci. Fabrairu 2024, J. Kamuwa da cuta, Shafi na 106130
MAGANIN LAFIYA 5,413 mai haƙuri ivermectin marigayi magani RCT: 36% ƙananan dogon Covid da 16% saurin murmurewa duk da jinkirin jinkiri, marasa lafiya marasa haɗari, da rashin kulawa. Yiwuwar fifiko> 0.999.
PRINCIPLE ya nuna 36% ƙananan ci gaba da ci gaba na takamaiman alamun Covid-19, p<0.0001118, kuma sakamakon farfadowa na farko yana nuna fifikon ivermectin tare da murmurewa da sauri da yuwuwar fifiko> 0.999. Yayin da marubutan suka yi iƙirarin da ba a taɓa gani ba cewa sakamakon bai dace da asibiti ba, kwanaki 2 cikin sauri murmurewa da 36% ƙananan dogon Covid duk sun dace sosai a asibiti. Saurin farfadowa yana da alaƙa da ƙananan mace-mace. Ingantacciyar ingantacciyar murmurewa da ƙarancin haɗarin dogon Covid tare da ivermectin, duk da jinkirin jinya, marasa lafiya marasa haɗari, da rashin kulawa. Bayanan ingantawa sun ɓace daga bayanan (cikakkun bayanai a mahaɗin da ke ƙasa). Ma'auni na p don ci gaba da farfadowa, dawwama da wuri da wuri, kawar da duk alamun bayyanar cututtuka, da kuma ci gaba da ci gaba duk <0.0001. Ingancin da ake gani don ivermectin a nan shi ne duk da gwajin da aka tsara shi ne a fili don gazawar gwaji, tare da babban ra'ayi a cikin ƙira, aiki, bincike, da rahoto. https://c19p.org/principleivm
89. S. Zubair, M. Chaudhry, A. Zubairi, T. Shahzad, A. Zahid, I. Khan, J. Khan, da Muhammad Irfan. Janairu 2022, Monaldi Archives na Cutar Ƙirji
MAGANIN LAFIYA 188 mai haƙuri ivermectin marigayi binciken magani: 9% mafi girma mace-mace (p=1) da 8% tsawon asibiti (p=0.4).
Marasa lafiya na asibiti 188 na baya-bayan nan a Pakistan, 90 sun yi maganin ivermectin, ba su nuna wani bambance-bambance da jiyya ba. Ƙungiyar ivermectin tana da cutar da ta fi tsanani (66% vs 58%, tare da 6x mafi girma haɗari ga marasa lafiya marasa lafiya)., da ƙarin marasa lafiya maza (70% vs. 65%). Yin amfani da remdesivir da steroids a cikin rukunin ivermectin kuma yana nuna cewa ivermectin ya fi dacewa a ba marasa lafiya a cikin yanayi mai tsanani. Babu wani illa da aka gani tare da ivermectin. Marubuta sun lura cewa an ga ingantaccen matakan ferritin tare da jiyya. Marubutan sun bayyana cewa marasa lafiya na ivermectin sun sami allurai na 2 12mg, 24 hours baya, amma daga baya sun bayyana cewa ba a daidaita sashi ba.. https://c19p.org/zubair
90. N. Kishoria, S. Mathur, V. Parmar, R. Kaur, H. Agarwal, B. Parihar, da S. Verma, Ivermectin a matsayin adjuvant zuwa hydroxychloroquine a cikin marasa lafiya da ke jure daidaitattun jiyya don SARS-CoV-2: sakamakon buɗaɗɗen lakabin bazuwar binciken asibiti. Agusta 2020, Paripex - Indiya J. Bincike, Shafi na 1-4
MAGANIN LAFIYA 32 mai haƙuri ivermectin marigayi magani RCT: 8% ƙananan fitarwa na asibiti (p=1) da 8% mafi muni mai saurin kamuwa da cuta (p=1).
Ƙananan RCT na marasa lafiya na asibiti a Indiya tare da 19 ivermectin marasa lafiya da 13 masu kula da marasa lafiya, tare da duk waɗanda ke karɓar ma'aunin kulawa ciki har da hydroxychloroquine, ba su nuna bambance-bambance masu mahimmanci ba.. Yawan marasa lafiya yana da ban sha'awa saboda binciken ya dauki marasa lafiya da ba su amsa ga daidaitaccen magani ba. Marubuta ba su bayyana jinkirin jinkirin ba amma yana iya yin latti saboda an riga an yi wa marasa lafiya magani na yau da kullun. Ba a bayar da sharuddan fitarwa ba. Ba a ƙayyade lokacin fitarwa ba kuma maiyuwa bai kasance daidai lokacin ba tun lokacin da aka fara jiyya ga duk marasa lafiya. Mawallafa sun nuna jiyya na 19 da marasa lafiya na 16, amma sakamakon kawai ya nuna marasa lafiya 13 kawai. Marubuta ba su nuna dalilin da ya sa sauran 3 suka ɓace ba. Bazuwar a cikin wannan ƙaramin samfurin ya haifar da bambance-bambance masu yawa a cikin ƙungiyoyi, tare da fiye da sau biyu a cikin ƙungiyar ivermectin tare da shekaru> 40, kuma kawai marasa lafiya 2 da shekaru> 60 duka a cikin rukunin ivermectin.. Marubuta ba su daidaita don waɗannan… https://c19p.org/kishoria
91. A. Soto, D. Quiñones-Laveriano, J. Azañero, R. Chumpitaz, J. Claros, L. Salazar, O. Rosales, L. Nuñez, D. Roca, da A. Alcantara, Mutuwa da abubuwan haɗari masu alaƙa a cikin marasa lafiya da ke asibiti saboda COVID-19 a cikin wani asibiti na Peruvian. Maris 2022, KUMA KUMA, Juzu'i na 17, fitowa ta 3, Shafi na e0264789
MAGANIN LAFIYA 1,418 mai haƙuri ivermectin marigayi magani binciken: 41% mafi girma mace-mace (p=0.001).
A baya-bayan nan 1,418 a ƙarshen mataki (46% mace-mace) marasa lafiya a Peru, suna nuna yawan mace-mace tare da ivermectin. Akwai rudani mai ƙarfi ta nuni; misali 48% na marasa lafiya tare da asali SpO2 <70% an bi da su idan aka kwatanta da 22% don SpO2>95%. Matsakaicin sakamakon Cox idan aka kwatanta da ƙididdigar taron shima yana goyan bayan wannan. Hakanan ana iya samun babban ruɗani ta lokaci tare da ƙayyadaddun kulawa da ke canzawa sosai a cikin 'yan watannin farko na cutar. Marasa lafiya na iya haɗuwa da waɗanda ke ciki [Soto-Becerra]. Sakamako a cikin tebur da rubutu ba su daidaita ba. https://c19p.org/soto
92. R. Ferreira, R. Beranger, P. Sampaio, J. Mansur Filho, da R. Lima, Sakamakon da ke da alaƙa da Hydroxychloroquine da Ivermectin a cikin marasa lafiya na asibiti tare da COVID-19: ƙwarewar cibiyar guda ɗaya. Nuwamba 2021, Revista da Associação Médica Brasileira, Juzu'i na 67, Fitowa ta 10, Shafi na 1466-1471
MAGANIN LAFIYA 102 mai haƙuri ivermectin marigayi magani binciken: 54% mafi girma hade mace-mace / intubation (p=0.37).
Marasa lafiya na asibiti 230 na baya-bayan nan a Brazil ba su nuna wani bambanci mai mahimmanci tare da maganin ivermectin. Marubuta sun lura cewa ana iya ba da jiyya ga marasa lafiya marasa lafiya. Marubuta sun lura cewa ba su sani ba idan an fara magani kafin ko bayan shigar da ICU da shigar da su. Baseline jimlar ƙirjin ƙirjin ƙirjin CT sun fi girma ga ivermectin (20% vs. 15%). An shigar da 25% na marasa lafiya a cikin kwanaki 3, idan aka kwatanta da kwanaki 5 don ivermectin. Kashi 38% kawai na marasa lafiya a hannun ivermectin an yi magani a cikin kwanaki 7, idan aka kwatanta da 61% na hydroxychloroquine. Waɗannan sun yi daidai da ivermectin da ake amfani da su don ƙarin marasa lafiya. Ba a san adadin sashi ba. https://c19p.org/ferreira2
93. . Martemucci, S. Martinez, J. Segovia, P. Reynoso, N. Sosa, M. Robledo, J. Guarrochena, M. Vernengo, N. Ruiz Diaz, E. Meza, da M. Aguirre, Ivermectin don hana asibitocin asibiti a cikin marasa lafiya tare da COVID-19 (IVERCOR-COVID19) gwajin da bazuwar wuri, gwaji sau biyu. Yuli 2021, BMC Cututtuka masu Yaduwa, Juzu'i na 21, Mas'ala ta 1
MAGANIN FARKO 501 mai haƙuri ivermectin farkon jiyya RCT: 33% ƙananan asibiti (p=0.23) da 5% mafi muni mai saurin kamuwa da cuta (p=0.55).
RCT tare da 501 ƙananan marasa lafiya marasa lafiya a Argentina suna nuna asibiti KO 0.65 [0.32-1.31]. Tare da asibiti 7% kawai, wannan gwajin ba shi da ƙarfi. Gwajin da farko ya haɗa da ƙananan marasa lafiya waɗanda ke murmurewa da sauri ba tare da magani ba, yana barin ƙaramin ɗaki don ingantawa tare da jiyya. Marasa lafiya 74 sun sami alamun cutar> = kwanaki 7. Daga cikin marasa lafiya 7 da ke buƙatar samun iska, Mawallafa sun lura cewa abin da ake bukata a baya a cikin rukunin ivermectin na iya zama saboda waɗancan marasa lafiya da ke da tsanani sosai a asali.. Duk da haka, marubuta sun san amsar wannan - ba a san dalilin da ya sa ba a ruwaito shi ba. Akwai ƙarin abubuwan da ba su da kyau a cikin rukunin placebo fiye da ƙungiyar ivermectin, suna ba da shawara mai yuwuwar batun tare da rarrabawa ko amfani da magunguna marasa gwaji. 25 +% na marasa lafiya an kwantar da su a cikin kwanaki 2/3 don kungiyoyin placebo / jiyya. https://c19p.org/vallejos2
94. M. Rezai, F. Ahangarkani, A. Hill, L. Ellis, M. Mirchandani, A. Davoudi, G. Eslami, F. Roozbeh, F. Babamahmoodi, N. Rouhani, A. Alikhani, N. Najafi, R. Ghasemian, H. Mehravaran, A. Hajialibaefar, M. Najavad, M. Najavad, M. Rahimzadeh, M. Saeedi, R. Alizadeh-Navai, M. Moosazadeh, S. Saeedi, S. Razavi-Amoli, S. Rezai, F. Rostami-Maskopaee, F. Hosseinzadeh, F. Movahedi, J. Markowitz, da kuma R. Valadan, Ba tare da Ƙaddamarwa ba CUTAR COVID 19; Sakamako na Bazuwar Guda Biyu, Makafi Biyu, Gwaje-gwajen Asibiti Mai Sarrafa Wuri Yuni 2022, Frontiers a Magunguna, Juzu'i na 9
MAGANIN FARKO 549 haƙuri ivermectin farkon jiyya RCT: 9%.
Farashin 549 marasa lafiya marasa lafiya a Iran. Sakamakon da aka ruwaito ya bambanta sosai da sakamakon da aka ƙayyade. An jera gwajin marasa lafiya daban. Ba a ba da rahoton sakamakon farko na asibiti da aka ƙayyade ba. Abubuwan da aka ruwaito na wannan sakamakon duka suna da kyau. Sakamakon da aka ƙayyade (ba a ba da rahoton 3 ba) [irct.ir]: - raguwa a cikin tari mai ci gaba da tachypnea da O2 jikewa sama da 94% - ba a ruwaito - korau PCR - rahoton - babban gunaguni dawo da lokaci - ba a ruwaito (kawai bayyanar cututtuka na mutum) - asibiti - rahoton - lokaci zuwa asibiti - ba a ruwaito - mace-mace - rahoton - sakamako masu illa - ya ruwaito a cikin daya kawai haƙuri (abin ban mamaki) Wani sabon sakamakon "dangi farfadowa" da aka ruwaito a cikin gwaji amma ba a ambata a cikin gwaji. Adadin da aka ruwaito da RR basu daidaita ba. Marubuta sun haɗa da wani mai bincike da aka kama akan bidiyo yana yarda cewa mai ba da kuɗi ya rinjayi yanke shawara akan binciken ivermectin: https://c19p.org/rezai3
95. D. Buonfrate, F. Chesini, D. Martini, M. Roncaglioni, M. Fernandez, M. Alvisi, I. De Simone, E. Rulli, A. Nobili, G. Casalini, S. Antinori, M. Gobbi, C. Campoli, M. Deiana, E. Pomari, G. Lunardi, da kuma High Te.ssari na R. jiyya na COVID-19 (binciken COVER): bazuwar, makafi biyu, cibiyar da yawa, lokaci na II, binciken kashi, tabbacin gwajin ra'ayi Satumba 2021, Int. J. Magungunan rigakafi, Shafi na 106516
MAGANIN FARKO 61 mai haƙuri ivermectin farkon jiyya RCT: 20% ingantacciyar kariya ta hoto (p=0.59).
Da farko ya ƙare 89 mai haƙuri RCT tare da babban kashi 29 da 32 babban adadin ivermectin marasa lafiya, suna nuna raguwar nauyin ƙwayar cuta mai dogaro da kashi, kodayake ba a kai ga ƙididdiga ba saboda farkon ƙarewa. Tun da yawancin marasa lafiya suna da ƙananan ƙwayar cuta a ranar 7, akwai ƙananan wuri don ingantawa tare da jiyya a ranar 7. Sakamakon tsaka-tsakin na iya nuna ci gaba mai girma, amma ba a ba da shi ba. Marubuta sun lura cewa ivermectin ya kasance mai aminci har ma da yawan adadin da aka yi amfani da shi, kodayake an rage haƙuri. Maƙarƙashiya ya yi ƙasa sosai a cikin hannu mai girma (~ 60%). Takardar ta ba da rahoton 4 SAEs, duk an warware su, tare da marasa lafiya na 3 a asibiti a cikin babban kashi na ivermectin, 1 a cikin babban kashi, da 0 a cikin hannun kulawa. Koyaya, ƙarin bayanan sun sabawa juna, suna nuna abubuwan da suka faru na aji 2 na 3 a cikin duka ivermectin makamai (cututtuka da cututtuka 2, da 2 Covid-19 pneumonia). Duk da yake wannan sakamakon ba shi da mahimmancin ƙididdiga, yana iya kasancewa a wani ɓangare saboda gazawar bazuwar. https://c19p.org/buonfrate
96. L. Shahbaznejad, A. Davoudi, G. Eslami, J. Markowitz, M. Navaeifar, F. Hosseinzadeh, F. Movahedi, da M. Rezai, Tasirin Ivermectin a cikin Marasa lafiya tare da COVID-19: Multicenter, Double-makafi, Randomized, Sarrafa gwaji na asibiti Janairu 2021, Clinical Therapeutics, Juzu'i na 43, Fitowa ta 6, Shafi na 1007-1019
MAGANIN LAFIYA 69 mai haƙuri ivermectin marigayi magani RCT: 32% farfadowa da sauri (p=0.05) da 15% guntu asibiti (p=0.02).
RCT a Iran yana nuna ɗan gajeren lokaci don murmurewa da ɗan gajeren lokacin asibiti tare da ivermectin. Babu wani sakamako mara kyau. Akwai mutuwa daya a cikin rukunin masu jiyya; mai haƙuri yana cikin mawuyacin hali a asali kuma ya mutu a cikin sa'o'i 24 na shiga. Hakanan duba [sciencedirect.com] da martanin marubucin [clinicaltherapeutics.com]. https://c19p.org/shahbaznejad
97. L. Jamir, M. Tripathi, S. Shankar, R. Kakkar, R. Ayyanar, da R. Aravindakshan, Masu Ƙaddamar da Sakamako Daga Cikin Mummunan Ma'aikatan 'Yan Sanda Tare da COVID-19: Nazarin Dubawa Daga Andhra Pradesh, Indiya Disamba 2021, Cureus
MAGANIN LAFIYA 266 mai haƙuri ivermectin ICU binciken: 53% mafi girma mace-mace (p=0.13).
Marasa lafiya 266 Covid-19 ICU na baya-bayan nan a Indiya, yana nuna ƙarancin mace-mace tare da PVP-I tabarbarewar baki da kuma amfani da hanci a kaikaice, da rashin ƙididdiga mafi girma na mace-mace tare da ivermectin da ƙananan mace-mace tare da remdesivir. https://c19p.org/jamir
98. H. Mikamo, S. Takahashi, Y. Yamagishi, A. Hirakawa, T. Harada, H. Nagashima, C. Noguchi, K. Masuko, H. Maekawa, T. Kashii, H. Ohbayashi, S. Hosokawa, K. Maejima, M. Yamato, W. Manosuthi, R. H. Paiboon, S. Kawamura, inganci da amincin ivermectin a cikin marasa lafiya tare da COVID-19 mai laushi a Japan da Thailand Satumba 2022, J. Kamuwa da cutar sankarau
MAGANIN FARKO 1,029 mai haƙuri ivermectin farkon jiyya RCT: 205% ci gaba mafi girma (p=0.49), 4% mafi muni ingantawa (p=0.62), da 4% inganta farfadowa (p=0.72).
RCT marasa lafiya marasa lafiya (yana nufin shekaru 35.7, SpO2 97.4) ba tare da nuna bambanci mai mahimmanci tare da saurin dawowa ba kuma kusan babu ci gaba a cikin ƙungiyoyin biyu. Ƙungiyoyin ba su da daidaito. Akwai 41% ƙarin marasa lafiya tare da dyspnea a asali a cikin rukunin jiyya. Hakazalika, a farkon marasa lafiya tare da alamun 4+ da aka zana 2+ sun fi kowa a cikin rukunin jiyya - 7% don ivermectin vs. 4% don placebo. Tebura S8 yana nuna shari'ar Covid-19 kawai na ciwon huhu. Marubuta sun ba da rahoton lokuta 3 da 1 na ci gaba; wannan yayi daidai da shari'o'in 3 da 1 na mummunan taron "Covid-19" a cikin Tebura S8. Ba a san yadda aka bayyana abubuwan da suka faru na Covid-19 ba tunda duk marasa lafiya ana nufin samun Covid-19. Ma'anar ci gaba na marubutan ya haɗa da "amfani da magungunan Covid-19" don haka mahimmancin ci gaban cuta ba a bayyana ba. An tsara binciken don samar da sakamako mara kyau tare da marasa lafiya masu ƙarancin haɗari, da kuma gudanar da ivermectin a kan komai a ciki. https://c19p.org/mikamo
99. C. De la Rocha, M. Cid-López, B. Venegas-López, S. Gómez-Méndez, A. Sánchez-Ortiz, A. Pérez-Ríos, R. Llamas-Velázquez, R. Llamas-Velázquez, A. Meza-Acuña, B. Vargas-Íñiguez, B. Vargas-Íñiguez, D.-Vázás-Galvá, D. Luna-Gudiño, C. Hernández-Puente, J. Milenkovic, C. Iglesias-Palomares, M. Méndez-del Villar, G. Gutiérrez-Dieck, C. Valderrábano-Roldán, J. Mercado-Cerda, J. Robles-Bojórquez, da kuma Sesmain a cikin asibitin da aka kwatanta da Iglesias-Bojórquez, da kuma asibitin I. Marasa lafiya na Mexiko tare da asymptomatic da m COVID-19: gwajin asibiti bazuwar Mayu 2022, BMC Cututtuka masu Yaduwa, Juzu'i na 22, Mas'ala ta 1
MAGANIN FARKO 56 mai haƙuri ivermectin farkon jiyya RCT: 15% murmurewa mafi muni (p=0.58) da 2% ingantacciyar kariya ta hoto (p=0.64).
Small RCT mara lafiya mai ƙarancin haɗari tare da 30 low-dose ivermectin da 26 kula da marasa lafiya, ba tare da wani sakamako na farko a kowane hannu ba. Kwayar cuta ta kwayar cuta ta kasance mafi mahimmanci tare da ivermectin a ranar 5, yayin da babu wani bambanci mai mahimmanci a ranar 1 ko rana ta 14. Babu wani bambanci mai mahimmanci a hade da bayyanar cututtuka; duk da haka, mawallafa sun haɗa da tari wanda shine mafi yawan alamar alama kuma yana iya dawwama bayan an kawar da kamuwa da cuta. Marasa lafiya na Ivermectin sun girmi shekaru 4 tare da mafi girman daidaitattun daidaito, suna da haɓakar kiba, ciwon sukari, hauhawar jini, da cututtukan zuciya, da ƙarancin kamuwa da cututtukan hanta da koda. Jinkirin cirewar ƙwayar cuta da aka gani na iya kasancewa a sashi saboda amfani da acetaminophen. Mawallafa sun kammala cewa "ivermectin ba shi da tasiri don hana ci gaba zuwa yanayi mai tsanani;" duk da haka babu wani ci gaba mai tsanani a kowane rukuni. https://c19p.org/delarocha
100. C. Bramante, J. Huling, C. Tignanelli, J. Buse, D. Liebovitz, J. Nicklas, K. Cohen, M. Puskarich, H. Belani, J. Proper, L. Siegel, N. Klatt, D. Odde, D. Luke, B. Anderson, A. Karger, N. Ingraham, V. K. Rat. Fenno, N. Avula, N. Reddy, S. Erickson, S. Lindberg, R. Fricton, S. Lee, A. Zaman, H. Saveraid, W. Tordsen, M. Pullen, M. Biros, N. Sherwood, J. Thompson, D. Boulware, da T. Murray, Randomized Trial of Metformin da Iver-19 Trial of Metformin Agusta 2022, NEJM, Juzu'i na 387, Fitowa ta 7, Shafi na 599-610
804 mai haƙuri ivermectin farkon magani RCT: 61% ƙananan asibiti don ivermectin vs. placebo (ba a ruwaito a cikin takarda ba wanda ke amfani da ƙungiyar kulawa ciki har da metformin), duk da jinkirin jinkiri, marasa lafiya marasa lafiya, da rashin kulawa. Sakamakon ER bai dace da alamomi ba.
RCT mai nisa na Covid-OUT, yana nuna babu wani bambance-bambance masu mahimmanci idan aka kwatanta da haɗuwar metformin/placebo "kungiyoyin sarrafawa". An jera sakamakon wasu jiyya daban - metformin, fluvoxamine. Authors hada da marasa lafiya na metformin a cikin rukunin kulawa, ƙyale cikakkun bayanai na gyare-gyare don tasiri sakamako. Yin amfani da daidaitattun jiyya vs. nazarin placebo yana nuna 61% ƙananan asibiti, ko 75% ƙananan ga marasa lafiya tare da farawa ≤5 kwanaki (ba ƙididdiga ba tare da abubuwan 7 da 5 kawai). Ba a ba da rahoton waɗannan sakamakon a cikin takarda ko ƙarin ƙarin ba, masu karatu suna buƙatar buƙatar bayanan. Akwai manyan batutuwa da yawa game da wannan binciken. Tsananin rashin daidaituwa don maganin ivermectin amma ba don kowane magani ko kulawa ba. Manyan abubuwan ƙidaya sun bambanta tsakanin takarda da rajista. Bayanan tushe sun bambanta tsakanin takarda da rajista. Ƙungiyar sarrafawa ta haɗa da metformin, keta yarjejeniya. Sakamakon farko yana canzawa. Sakamakon da yawa sun ɓace, gami da lokacin dawowa. Protocol shafi na 12 yana cewa "Masana kididdigar ƙungiyar binciken za su kasance makanta” yayin da Karin bayanai shafi na 40 ke cewa “Akwai ƙwararren ƙididdiga ɗaya mara makafi tare da ƙwararrun ƙididdiga masu tallafawa biyu marasa makafi akan ƙungiyar binciken.” Bayar da magani ya bambanta sosai akan gwajin. A wannan gabatarwar, Mawallafa sun nuna cewa bayarwa ya kasance na farko na gida, daga baya ta hanyar FedEx, ya kasance da hankali sosai a cikin watan Agusta, akwai jinkiri saboda matsalolin bandwidth na tawagar, kuma sun gane cewa za su iya amfani da FedEx bayarwa a ranar Satumba. Jiyya ya kasance kwanaki 14 don metformin da fluvoxamine, amma kwanaki 3 kacal don ivermectin. Rikowa ya yi ƙasa sosai, tare da 77% gabaɗayan rahoton 70+% riko, da 85% don rahoton ivermectin 70+% riko. Wani marubuci ya yi iƙirarin kashi 85% ya ɗauki duk allurai amma hakan ya saba wa 20% da aka ruwaito "Jimillar Katsewa ko Kashewa" a cikin Teburin S2. Marubuta suna nuna jinkiri har zuwa kwanaki 5 a cikin amfani na zahiri. Marubuta sun lura da jinkirin jinkiri na kwanaki 11 tare da gwajin asibiti mai nisa idan aka kwatanta da har zuwa kwanaki 5 don "real-duniya amfani" @ 43: 00, inda kwanakin 5 suka samo daga gwaji da jinkirin tsarin likita. Duk da haka, amfani da ainihin duniya, kamar yadda aka yi amfani da shi a wurare da yawa, shine a sami magani a hannu don ɗaukar shi nan da nan bayan bayyanar cututtuka. Ƙungiyar kulawa ta haɗa da metformin, cin zarafin yarjejeniya. Sakamakon metformin) Marubuta sun lura cewa "asibiti watakila shine mafi daidaito kuma ingantaccen bayanin ƙarshen ƙarshen.” Cikakken cikakken bincike na wannan binciken saboda yaɗuwar latsa ba daidai ba shine a: https://c19p.org/covidoutivm
101. A. Krolewiecki, A. Lifschitz, M. Moragas, M. Travacio, R. Valentini, D. Alonso, R. Solari, M. Tinelli, R. Cimino, L. Álvarez, P. Fleitas, L. Ceballos, M. Golemba, F. Fernández, D. Fernandez, J. Farina, G. Cardama, A. Mangano, E. Spitzer, S. Gold, da C. Lanusse, Antiviral sakamako na ivermectin mai girma a cikin manya tare da COVID-19: Gwajin bazuwar hujja Yuni 2021, Magungunan Magunguna, Juzu'i na 37, Shafi na 100959
MAGANIN FARKO 41 mai haƙuri ivermectin farkon jiyya RCT: 66% ingantaccen nauyin hoto (p=0.09).
Tabbacin ra'ayi RCT tare da 30 ivermectin marasa lafiya da 15 kula da marasa lafiya, yana nuna ƙaddamar da aikin antiviral, amma babu wani bambanci mai mahimmanci a sakamakon asibiti. Babu wani bambanci mai mahimmanci a cikin raguwar nauyin ƙwayar cuta tsakanin ƙungiyoyi gaba ɗaya, amma an sami babban bambanci a cikin marasa lafiya tare da matakan ivermectin na plasma mafi girma (72% vs. 42%, p=0.004). Ma'ana ivermectin matakin maida hankali na plasma yana da alaƙa tare da ƙimar lalata ƙwayar cuta (r=0.47, p=0.02). Ana ba da canji a cikin nauyin hoto don ƙungiyoyin <160ng/mL da> 160ng/mL, amma ba duka ƙungiyar jiyya ba. Corrigendum yana ba da ƙimar lalatawar ƙwayar cuta ta mutum don ƙididdige ƙimar ruɓar ƙwayar cuta gabaɗaya. Marubuta sun buga a corrigendum. https://c19p.org/krolewiecki
102. S. Naggie, D. Boulware, C. Lindsell, T. Stewart, N. Gentile, S. Collins. Dunsmore, S. Adam, A. DeLong, G. Hanna, A. Remaly, R. Wilder, S. Wilson, E. Shenkman, A. Hernandez, W. Vincent, R. Vincent, R. Bianchi, J. Premas, D. Cordero-Loperena, E. Rivera, M. Gupta, G. Ziida S. Ramin, J. Nataraj, M. Paasche-Orlow, L. Henault, K. Waite, D. Miller, G. Brounce, C. George-Adebayo, A. Adebayo, J. Wallan, A. Slandzicki et al. Yuni 2022, Jama, Juzu'i na 328, Fitowa ta 16, Shafi na 1595
MAGANIN LAFIYA 1,591 mai haƙuri ivermectin marigayi magani RCT: 99%, 98%, 97% yuwuwar inganci na baya don ma'anar rashin lafiya da ci gaba na asibiti @14 da 7 days, duk da jinkirin jinkiri, marasa lafiya marasa lafiya, da rashin kulawa. Duk sun wuce madaidaicin ƙayyadaddun ƙofa don fifiko. An canza sakamakon ci gaba na asibiti ba tare da bayani ba a cikin sigar gaba.
Babban rikice-rikice na sha'awa, rashin daidaiton bayanai, kurakuran da ba a daidaita su ba, babu amsa daga marubuta, zamba na mahalarta, ƙin sakin bayanai, amma wanda ba zai taɓa sanin hakan ta hanyar karanta kanun labarai daga littafin ba. New York Times. RCT ƙananan marasa lafiya marasa lafiya tare da jinkirin jinkiri (kwanakin 6 na tsakiya, 25% ≥8 kwanaki) a cikin Amurka, yana nuna yiwuwar 98% na tasiri don ci gaba na asibiti a ranar 14, dangantakar jinkirin jinkiri, da tasiri mai mahimmanci ga marasa lafiya tare da alamun bayyanar cututtuka a asali. 1) An aika da magungunan ga marasa lafiya ta hanyar mail, ta yadda wasu majiyyatan suka sha su kwanaki 13 ko 14 bayan bayyanar cututtuka. 2) Mawallafa ba su taba ganin yawancin marasa lafiya ba, kuma kowane mataki na tsari an yi shi da sauri. Suna kiran wannan gwajin "rabawa". 3) Babu wani rahoto game da bin doka a cikin gwaji, don haka ba mu san ko da yawa daga cikin marasa lafiya sun dauki adadin nawa aka ba su ba. 4) Babu wani bincike-bincike na kowane tsari, don haka ba mu san yadda maganin ya yi ba a cikin marasa lafiya waɗanda a zahiri sun ɗauki duk allurai.
Kuma har yanzu, sakamakon yana da ƙarfi sosai ga ivermectin, idan kun cire son zuciya. Marubutan sun rubuta cewa akwai "yiwuwar fa'idar 0.91 na baya." Wannan wata hanya ce ta rubuta cewa sun sami kashi 91% na yiwuwar cewa ivermectin ya fi ɗaukar placebo, a rage lokacin dawowa. Yiwuwar ivermectin na baya yana da tasiri shine 99%, 98%, 97% na matsakaicin lokaci mara lafiya da ci gaban asibiti @14 da 7 days. Duk sun wuce madaidaicin ƙayyadaddun ƙofa don fifiko. Lura cewa ci gaban asibiti yana haifar da wuce gona da iri a cikin preprint canza a cikin sigar jarida don hannun 400µg/kg, ba tare da wani bayani ba sama da kwanaki 500). Naggie ya ba da rahoton hannun 600µg/kg daban. Lokacin da ba a fayyace ba, sharhi yana komawa ga hannun 400µg/kg (ƙananan kashi). Marubutan ba kawai ba canji farkon ƙarshen ƙarshen; Wadanda aka yi wa rajista a kan clinicaltrials.gov (Asibiti, Mutuwa, Alamun da rana ta 14) ba a ma bayar da rahoto a cikin takarda ba. The Siga na 4 na ƙa'idar gwaji ba da rahoton ainihin ƙarshen ƙarshen, yana nuna kamar ana auna shi kwanaki 28 bayan rajista, yayin da Sigar farko ta yarjejeniya-da kuma clinicaltrials.gov- ba da rahoto kamar yadda aka auna kwanaki 14 bayan rajista. "ACTIV-6 ya sanya ƙungiyar gwaji tare da zama masu gaskiya idan aka kwatanta."
Don majiyoyin zargi, duba kuma: Gwajin ACTIV-6 akan Ivermectin: Masana Kimiyya na NIH Suna Mummuna da kuma Labarin Wani Majinyaci na Gaskiya ACTIV-6 da kuma ACTIV-6 Dosing & Lokaci: Fox A cikin Gidan Hen. Akwai ƙarin cikakkun bayanai game da wannan binciken saboda yaɗuwar latsa ba daidai ba a: https://c19p.org/activ6ivm
103. P. Sarojvisut, A. Apisarnthanarak, K. Jantarathaneewat, O. Sathitakorn, T. Pienthong, C. Mingmalairak, D. Warren, da D. Weber, Buɗaɗɗen Lakabi Mai Rarraba Gwajin Gudanar da Ivermectin Plus Favipiravir-Based Standard of Care with Favipiravir-Based Standard of Care tare da Favipiravirde-Bassed Standard of Care for COVID-19. Disamba 2022, Kamuwa da cuta & Chemotherapy, Juzu'i na 54
MAGANIN LAFIYA 317 mai haƙuri ivermectin marigayi magani RCT: 104% shigar da ICU mafi girma (p=0.62), 104% mafi muni ingantawa (p=0.62), da 4% saurin dawowa (p=0.63).
RCT marasa lafiya marasa lafiya a asibiti a Thailand ba su nuna wani bambanci mai mahimmanci tare da ƙari na ivermectin zuwa favipiravir tushen kulawa. Abstract kawai yana samuwa a halin yanzu. An yi rajistar gwajin a baya. Sakamakon farko shine haɓaka ma'auni na daidaitattun nau'in WHO na maki 2 a cikin kwanaki 3, 7, 14, 21, wanda kawai lokacin da ba a bayyana ba (lokacin da kusan duk marasa lafiya sun murmure) aka ba da su a cikin taƙaitaccen bayani. Rijistar ta nuna cewa an ba da sa hannun ne kawai "bayan sakamakon dakin gwaje-gwaje"(?) ba tare da bayani ba. https://c19p.org/sarojvisut
-
Dokta David Gortler masanin ilimin harhada magunguna ne, likitan harhada magunguna, masanin kimiyyar bincike kuma tsohon memba na Babban Jami'in Gudanarwa na FDA wanda ya zama babban mai ba da shawara ga Kwamishinan FDA akan al'amuran: Al'amuran ka'idoji na FDA, amincin magunguna da manufofin kimiyya na FDA. Shi tsohon jami'ar Yale ne da kuma jami'ar Georgetown didactic farfesa a fannin harhada magunguna da fasahar kere-kere, tare da sama da shekaru goma na koyar da ilimin kimiyya da bincike na benci, a zaman wani bangare na kwarewarsa ta kusan shekaru ashirin a ci gaban muggan kwayoyi. Shi babban ɗan'uwa ne a fannin kiwon lafiya da manufofin FDA a Gidauniyar Heritage a Washington DC da 2023 Brownstone Fellow.
Duba dukkan posts
